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SUMMARY 
 
The identification of universal tumor-specific antigens (TSA) shared between multiple patients 
and/or multiple tumors is of great importance to overcome the practical limitations of 
personalized cancer immunotherapy. Recent studies support the involvement of DEPDC1 in many 
aspects of cancer traits, such as cell proliferation, anti-apoptosis and cell invasion, suggesting that 
it may play key roles in the oncogenic process. In this study, we report that DEPDC1 expression is 
up-regulated in several types of human tumors, and closely linked to a poorer prognosis; 
therefore, it might be regarded as a novel universal oncoantigen potentially suitable for targeting 
many different cancers. In this regard, we report the identification of an immunogenic DEPDC1-
derived epitope restricted for the HLA-A*0201 molecule, which is able to induce cytotoxic T 
lymphocytes (CTL) exerting a strong and specific functional response in vitro in response not only 
to peptide-loaded cells but also to triple negative breast cancer (TNBC) cells endogenously 
expressing the DEPDC1 protein. Such CTL are also therapeutically active against human TNBC 
xenografts in vivo upon adoptive transfer in immunodeficient mice. Overall, these data provide 
evidences that this DEPDC1-derived antigenic epitope can be exploited as a new tool for the 
development of immunotherapeutic strategies for HLA-A*0201 patients with TNBC, and 
potentially many other cancers. Moreover, we plan to employ an approach of multiplexing digital 
pathology to study the intimate relationships that adoptively transferred lymphocytes can 
establish with TNBC cells in tumor-bearing mice, as further advances in immunotherapy 
approaches require a detailed understanding of cell dynamics within the tumor 
microenvironment. The benefits of multispectral immunohistochemistry, combined with the 
development of software for quantitation, are making this methodology an increasingly powerful 
tool in the analysis and characterization of tissue and cellular processes, supporting diagnostic 
potential in order to improve therapies.  
2 
 
3 
 
RIASSUNTO 
 
L’identificazione di antigeni tumore-specifici universali condivisi tra più pazienti e/o tra più tumori 
diversi, è di grande importanza per superare le limitazioni pratiche dell’immunoterapia oncologica 
personalizzata. Il coinvolgimento di DEPDC1 in molti aspetti del processo tumorale, come, ad 
esempio, nella proliferazione cellulare, nell’anti-apoptosi e nell’invasione cellulare, è stato 
supportato da lavori pubblicati di recente, suggerendo che tale proteina possa svolgere ruoli 
chiave nel processo oncogeno. In questo studio riportiamo che l’espressione di DEPDC1 è sovra-
regolata in molti tipi di tumori umani, e strettamente collegata ad una prognosi avversa; per 
questo motivo DEPDC1 può essere considerato come un nuovo antigene tumorale universale 
potenzialmente adatto per il targeting di molti tumori diversi. A questo proposito, riportiamo 
l’identificazione di un epitopo immunogenico derivato da DEPDC1 ristretto per la molecola HLA-
A*0201, capace di indurre linfociti T citotossici (CTL) esercitanti una forte e specifica risposta 
funzionale in vitro, in risposta non solo a cellule caricate con il peptide ma anche in risposta a 
cellule di tumore al seno triplo negativo (TNBC) che esprimono in modo endogeno la proteina 
DEPDC1. Tali CTL sono anche attivi in modo terapeutico in vivo, in seguito al loro trasferimento 
adottivo in topi immunodeficienti, nei confronti di xenotrapianti di cellule di TNBC umane. 
Complessivamente, questi dati forniscono evidenze a supporto dell’uso di questo epitopo 
antigenico derivante da DEPDC1 come un nuovo strumento per lo sviluppo di strategie 
immunoterapeutiche per pazienti HLA-A*0201 con TNBC, e potenzialmente con molti altri tipi di 
tumore. Inoltre, poiché ulteriori miglioramenti negli approcci di immunoterapia necessitano di una 
comprensione dettagliata delle dinamiche cellulari all’interno del microambiente tumorale, 
programmiamo di usare un approccio di multiplexing digital pathology per studiare le strette 
relazioni che i linfociti adottivamente trasferiti possono stabilire con le cellule di TNBC in topi 
portanti il tumore. I benefici dell’immunoistochimica multispettrale, combinati con lo sviluppo di 
software per la quantificazione, stanno rendendo questa metodologia un strumento sempre più 
potente nell’analisi a nella caratterizzazione di processi tessutali e cellulari, supportando il 
potenziale diagnostico con lo scopo di migliorare le terapie.  
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INTRODUCTION 
 
1. Cancer and the immune system 
Immunology, long considered not to be a critical discipline to understand cancer mechanisms, has 
provided today new important evidences for a comprehensive view of tumor biology. Until 
recently, investigations into the nature of cancer focused strictly on the cancer cells and on cancer 
as a genetic disease, while nowadays there is an increased emphasis on studying cancer as a 
systemic disease; this has led to move the focus to the host and to the microenvironment in which 
the cancer grows, such as the immune system. As a result, in 2011 a new picture of cancer has 
emerged: cancer is considered to be able to modify or reprogram its cellular metabolism, to 
maintain its genome instable and mutable, to avoid immune destruction, and, finally, to induce 
the chronic inflammation that promotes its growth rather than elimination 1. The last two 
hallmarks highlight the newly recognized dual interaction between cancer and the immune 
system.  
The first indication that the immune system can recognize and reject tumors, a concept known as 
cancer immunosurveillance, came from animal models in which tumors were rejected. In 
particular, mice lacking an intact immune system were shown to be more susceptible to 
carcinogen-induced and spontaneous cancers, as compared with their immunocompetent 
counterparts 2. Studies of cancer-immune system interactions revealed that every known innate 
and adaptive immune effector mechanism participates in tumor recognition and control 3. The first 
few transformed cells are detected by NK cells through specific ligands on surface of tumor cells. 
This leads initially to their destruction, and then to the uptake and processing of their fragments 
by the macrophages and dendritic cells that in turn, are activated to secrete inflammatory 
cytokines, such as Interferon-γ (IFN-γ). The tumor cell-derived peptides are then presented to 
CD8+ and CD4+ T cells on the Human Leucocyte Antigen (HLA) class I and II, respectively. The 
activation of T lymphocytes leads to the production of additional cytokines that further promote 
activation of innate immunity, and support the expansion and production of tumor-specific 
cytotoxic T cells (CTL) and antibodies by B lymphocytes. B cells secrete specific antibodies causing 
the lysis or the phagocytosis of cells that display tumor antigens, while CTLs use their T cell 
receptor (TCR) to specifically recognize small cell-derived peptides presented on cell surface 
bound to MHC class I molecules, and release cytotoxic molecules and cytokines that kill the tumor 
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cells and activate nearby immune cells. CD4+ helper T cells promote the activation of both B cells 
and CTLs. In this way, the adaptive immune system can eliminate remaining tumor cells and, 
importantly, can generate an immune memory to specific tumor components that prevent tumor 
recurrence. On the other hand, immunity shapes the intrinsic nature of developing tumors 
through the immunological pressure afforded by cancer immunosurveillance. The combination of 
the host-protective and the tumor-sculpting functions of the immune system during the tumor 
development is termed cancer immunoediting 4. This process can have at least three different but 
related outcomes: elimination, equilibrium and escape 5 (Figure 1). A highly immunogenic tumor in 
a immunocompetent individual will results in optimal stimulation of the innate immune system 
leading to the production of immunostimolatory cytokines, acute inflammation and activation of a 
large number of T and B cells, which make possible a prompt elimination of the arising tumor. A 
less immunogenic tumor leads to the survival of some cancer cells that nevertheless remain under 
immunosurveillance. Into this dynamic equilibrium phase, the slow growth of the tumor would be 
accompanied by repeated activation of the immune system and the elimination of some tumor 
cells, followed by further cycles of tumor regrowth and immune-mediated destruction. During this 
period of Darwinian selection, many of the original escape variants of the tumor cells are 
destroyed, but new variants arise, carrying different mutations that provide resistance to the 
immune attacks. The equilibrium phase is the longest of the three processes and could last life-
long, or be disturbed by changes in the tumor that allow it to avoid immunosurveillance (i.e. the 
loss of tumor antigens or co-stimolatory molecules 6) or changes in the immune system that weak 
the tumor surveillance (i.e. factors secreted by tumor cells that inhibit T cells, such as TGF-β). The 
tumor escape is caused also by an increase of immunosuppressive cells, such as regulatory T cells 
(Treg), myeloid-derived suppressor cells (MDSC), immunosuppressive cytokines derived from Treg, 
MDSC and tumor cells, and co-inhibitory molecules that inhibit the T cell activation, such as CTLA-4 
and PD-1 7.  This results in a clinically observable malignant disease. 
7 
 
 
Figure 1. The three phases of the cancer immunoediting process. Normal cells (gray) subject to 
common oncogenic stimuli ultimately undergo transformation and become tumor cells (red) (top). 
Even at early stages of tumorigenesis, these cells may express distinct tumor-specific markers and 
generate proinflammatory “danger” signals that initiate the cancer immunoediting process 
(bottom). Image from Dunn et al. Immunity, 2004. 
 
2. Tumor antigens 
Effectors of adaptive immunity, such as CD4+ helper T cells, CD8+ cytotoxic T cells and antibodies 
specifically target tumor antigens. The molecular nature of antigens recognized by CTL on tumors 
was revealed in 1989, when Lurquin et al. showed that a mouse tumor-specific CTL population 
recognized a peptide derived from a self-protein, mutated in cancer cells 8. This observation led to 
the concept that MHC class I molecules continuously display on the cell surface peptides of 8 to 10 
amino acids that are derived from a wide variety (if not all) of intracellular proteins processed by 
the proteasome (the so called “antigen processing pathway”) 9. In tumors, some of these peptides 
originate from altered or aberrantly expressed proteins, thereby marking the cells for CTL 
recognition and killing through the release of cytotoxic molecules and cytokines that stimulate the 
activation of adjacent immune cells 10 (Figure 2).  
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Figure 2. Processing of tumor antigens that are recognized by CD8+ T cells. Image from Coulie et 
al. Nature Reviews Cancer, 2014. 
 
Tumor antigens have been tested as vaccines, targets for monoclonal antibodies and targets for 
adoptively transferred cytotoxic T cells. To be safe and efficient, immunotherapy strategies should 
elicit efficient T cell responses against antigenic peptides that are present on tumor cells but not 
on healthy cells, in order to avoid autoimmune side effects 11. Such cancer rejection epitopes may 
be derived from two classes of antigens: a first one is formed by Tumor-Associated Antigens (TAA), 
which are highly overexpressed in tumors but can also be found in normal tissues; the second class 
is formed by Tumor-Specific Antigens (TSA), which are exclusively expressed in tumor tissues 
(Figure 3).  
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Figure 3. Classes of human tumor antigens that are recognized by T lymphocytes. Image from 
Coulie et al. Nature Reviews Cancer, 2014. 
 
2.1 Tumor-associated antigens (TAA) 
This category of antigens comprises differentiation antigens and antigens derived from 
genes that are overexpressed in tumors 12. 
 
- Differentiation antigens. Differentiation antigens are derived from proteins that are 
expressed only in a given type of tumor and in the corresponding healthy tissue. Most 
of differentiation antigens identified thus far are present on melanoma cells, in which 
the corresponding protein is often involved in melanin biosynthesis or melanosome 
biogenesis 13. Interestingly, spontaneous responses to peptides derived from proteins 
such as tyrosinase 14, gp100 15, Melan-A/MART-1 16 or gp75/TRP1 17 are frequent in 
melanoma patients and healthy donors 18, suggesting that central tolerance to these 
antigens is not complete. T cell responses to differentiation antigens can lead to 
vitiligo, a partial skin depigmentation often observed in melanoma patients and 
generally associated with a good prognosis 19. Peptides were also identified from the 
prostate specific antigen (PSA) and the prostatic acidic phosphatase, two proteins 
expressed in normal prostate and tumor prostate tissues 20,21. Moreover, the 
carcinoembryonic antigen (CEA) is often highly expressed in colorectal cancer and 
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other epithelial tumors but is also present at lower level in a variety of normal 
epithelial cells of the intestinal tract 22. Antigens of this group are not tumor-specific, so 
their use as targets for cancer immunotherapy may result in autoimmunity towards the 
corresponding normal tissue, if not removed, as the case of PSA 23. 
 
- Overexpressed antigens. Overexpression of proteins in tumors may provide an 
opportunity for a specific T cell response, as a threshold level of antigen expression on 
the cell surface is required for recognition by T cells. However, the reliability of the 
quantification of their amounts on the surface of cancer cells versus normal cells is 
difficult to define 24. Examples of peptides derived from overexpressed genes include 
those derived from the inhibitor of apoptosis protein Survivin 25, the wild-type p53 
protein 26,  the oncogene and growth factor receptor ERBB2 (HER2/NEU), which is 
overexpressed in many epithelial tumors including ovarian and breast carcinoma 27. 
Peptides are also derived from the protein Wilms tumor 1 (WT1), a transcription factor 
expressed at 10- to 1000-fold higher levels in leukemic versus normal cells 28. In 
leukemia patients receiving an allogenic hematopoietic cell transplant, followed by an 
infusion of donor-derived CTL recognizing the WT1-derived HLA-A2-restricted peptide, 
a decrease in the number of leukemic cells was observed, without evidence of 
autoimmune toxicity 29. As overexpressed antigens are shared by numerous tumors, 
they represent attractive targets for the development of immunotherapy; however, 
their use is not devoid of the risk of developing autoimmune reactions due to the low 
but still detectable expression of the corresponding genes in healthy tissues. 
 
2.2 Tumor-specific antigens (TSA) 
There are three classes of antigens with a tumor-specific expression pattern 12: antigens 
derived from viral proteins, from point mutations, and encoded by cancer-germline genes. 
As compared with tumor-associated antigens, TSA have been postulated to be of particular 
relevance to tumor control, as the quality of T cell pool that is available for these antigens 
is not affected by central T cell tolerance 30.  
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- Viral antigens. Viruses are at the origin of several types of cancers, for example  
cervical carcinoma, nasopharyngeal carcinoma, hepatocarcinoma and some leukemias 
31. Vaccines containing long Human papilloma virus peptides (HPV) recently emerged as 
a promising therapeutic modality for HPV-related cancers, as they increase the number 
and activity of HPV-16-specific CD4+ and CD8+ T cells 32.  
 
- Antigens encoded by mutated genes. Many CTL isolated from the blood or tumors of 
cancer patients were found to recognize antigens that arise from point mutations in 
ubiquitously expressed genes 33. In most cases, the mutation changes one amino acid 
in the peptide sequence, either enabling the peptide to bind to the MHC class I 
molecule or creating a new antigenic determinant that is recognized by the CTL. In 
some cases, the mutation causes a frameshift leading to the production of a new 
antigenic peptide 34. The CDK4 gene mutation, for example, affect the binding of CDK4 
to its inhibitor p16/INK4a receptor,  favoring uncontrolled cell division 35. In most cases, 
however, these mutations are passenger mutations (mutations that have no effect on 
the fitness of the tumor but may be associated with a clonal expansion) and the 
corresponding antigenic peptides are unique to the tumors in which they were 
identified. Tumors with a high mutation rate, such as melanoma or lung carcinoma, 
have more mutated antigens and therefore they are more immunogenic 36. Another 
oncogenic process involves chromosomal translocations. In this case, the breakpoints 
can code for chimeric peptides that can be processed in the tumor cells and presented 
on HLA molecules. Such peptides from BCR-ABL or ETV6-AML1 fusion proteins are 
recognized by T cells in leukemic patients 37,38.  
 
- Cancer-germline genes. This class of tumor-specific antigens are expressed in a wide 
variety of cancer types but not in normal tissues except in testicular germline and 
placenta trophoblastic cells, and include the melanoma-antigen encoding (MAGE) 39, 
BAGE 40 and  GAGE 39 gene families, all located on the X chromosome. Their tumor-
specific pattern expression results from the demethylation of their promoter sequence, 
as part of a genome-wide demethylation that takes place in male germ cells and in 
some advanced cancers 41. Because male germline cells and trophoblastic cells do not 
display MHC class I molecules on their surface 42, they cannot display antigens to T 
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cells. This class of antigens appear to be strictly tumor-specific and their use as 
immunotherapeutic targets in cancer vaccination or in adoptive T cells transfer should 
not be deleterious to the patient.         
 
3. Cancer immunotherapy 
Immunotherapy, which aims to enhance the cancer patient’s immune system by improving its 
ability to recognize the tumor or providing a missing immune effector function, is a treatment 
approach that holds promise of a life-long cure 43. The most convincing evidence for existence of 
antitumor activity came from clinical trials performed in the late 1980s. These trials showed that 
some metastatic melanoma and renal cell carcinoma patients experienced dramatic tumor 
regressions in response to treatment with the cytokine interleukin (IL)-2, which was known to 
have no direct tumoricidal capacity but was instead a potent activator of cytotoxic T lymphocytes 
44. Although most patients progressed on IL-2 therapy, almost 15% of patients had objective 
responses, and half of these went on to be completely cured 45,46. These results led the US Food 
and Drug Administration (FDA) to approve IL-2 in the late 1990s as the first bona fide 
immunotherapy for the treatment of cancer patients. They also inspired several research studies 
over the past two decades, to develop alternative immunotherapies with better safety and 
efficacy and to improve the understanding of IL-2 mechanism of action. Over the last decade, 
great efforts have been dedicate to the development of interventions that mediate antineoplastic 
effects by initiating a novel or boosting an existing immune response against neoplastic cells 47,48. 
This intense wave of preclinical and clinical investigation culminated with the approval of various 
immunotherapeutic interventions for use in humans. Clinical studies are being initiated at an ever 
accelerating rate to test the safety and efficacy of various immunotherapeutic regimens in cancer 
patients, either alone or combined with other antineoplastic agents 49. The hopes generated by 
these approaches are immense, and several other forms of immunotherapy are expected to 
obtain regulatory approval within the next few years (Figure 4).  
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Figure 4. Anticancer immunotherapy. Image from Galluzzi et al. Oncotarget, 2014. 
 
Anticancer immunotherapies are generally classified as “active” or “passive” based on their ability 
to activate the host immune system against cancer cells. In this way, anticancer vaccines and 
checkpoint inhibitors exert anticancer effects only upon the engagement of the host immune 
system, constituting clear examples of active immunotherapy 50,51. Conversely, tumor-targeting 
monoclonal antibodies (mAbs) and adoptively transferred T cells are considered passive forms of 
immunotherapy, as they are endowed with intrinsic antineoplastic activity 52,53. An alternative 
classification of immunotherapeutic anticancer regimens is based on antigen-specificity: thus, 
while tumor-targeting mAbs are widely considered antigen-specific interventions, 
immunostimolatory cytokines or checkpoint blockers activate anticancer immune responses of 
generally broad specificity. 
 
3.1 Active immunotherapy 
- DC-based immunotherapy. Several forms of DC-based immunotherapy have been 
developed, most of which involve the isolation of patient- or donor-derived circulating 
monocytes and their amplification, differentiation and maturation ex vivo 54. More 
often, autologous DCs are re-infused into cancer patients upon exposure to a source of 
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TAAs, including TAA-derived peptides 55, mRNAs coding for one or more specific TAAs 
56, expression vectors coding for one or more specific TAAs 57, bulk cancer cell lysates 58 
or bulk cancer cell-derived mRNA 59. As an alternative, DCs are allowed to fuse ex vivo 
with inactivated cancer cells, generating the dendritomes 60. The rationale behind of 
these approaches is that DCs loaded ex vivo with TAA or TAA-coding molecules, 
become able to prime TAA-targeting immune responses upon reinfusion in cancer 
patients. TAA are fused to mAbs, polypeptides or carbohydrates that selectively bind to 
DCs 61,62, encapsulated in DC-targeting immunoliposomes 63 or encoded by DC-specific 
vectors 64. Sipuleucel-T (also known as Provenge) was the first therapeutic DC-based 
cancer vaccine approved in 2010 by FDA for the therapy of asymptomatic or minimally 
symptomatic metastatic castration-refractory prostate cancer 65. Sipuleucel-T consist of 
autologous professional antigen-presenting cells (APCs) activated with a fusion protein 
(PA2024) between the prostatic acid phosphatase and the immunostimolant GM-CSF. 
Despite an overall survival benefit of 4.1 months was demonstrated compared to 
placebo, the challenge of producing sufficient vaccine for the target population and the 
costs of this treatment led the producing company (Dendreon) to stop production and 
bankruptcy 66.    
 
- Peptide- and DNA-based anticancer vaccines. A successful therapeutic cancer vaccine 
activates the cancer patient’s immune system, resulting in eradication or long-term 
control of disease. A vaccine typically consists of a full-length recombinant TAAs or 
peptides in an immunogenic formulation (adjuvants which promote DC maturation) 
administered to cancer patients, most often intramuscularly, subcutaneously or 
intradermally 67,68. In this way, resident DCs (or other APCs) acquire the ability to 
present the TAA-derived epitopes while maturing, hence priming a robust TAA-specific 
immune response. The mechanisms underlying the priming of anticancer immune 
responses by peptide-based vaccines, and therefore their efficacy, depend (at least in 
part) on their size. Thus, while short peptides (8-12 amino acids) are designed to 
directly bind to MHC molecules expressed on the surface of APCs, long peptides (25-30 
residues) must be endocytosed, processed and presented by APCs for eliciting an 
immune response 50. Normally, the therapeutic activity of long peptides is superior to 
the short counterparts, especially when they include epitopes recognized by both CTL 
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and CD4+ helper T cells, or when conjugated to efficient adjuvants 69. A peculiar type of 
peptide-based vaccines include autologous tumor lysates complexed with 
immunostimulatory chaperons. However, generating personalized anticancer vaccines 
is associated with considerable costs 70. 
DNA-based anticancer vaccines are based on TAA-coding constructs, naked or vectored 
by viral particles, non-pathogenic bacteria or yeast cells, and transform APCs or 
muscular cells that become a source of such TAA 71. A particularly interesting approach 
in this context is represented by oncolytic viruses genetically altered to code for the 
TAA, called oncolytic vaccines 72. The most successful cancer vaccine to date is the 
vaccination against human papilloma virus (HPV) 73 to prevent the cervical cancer. 
 
- Immunostimolatory cytokines. Various attempts have been made to harness the 
biological potency of specific cytokines to elicit novel or reinvigorate pre-existent 
tumor-targeting immune responses 74. The administration of most of the 
immunostimolatory cytokines alone to cancer patients, is however associated with 
little, if any, clinical activity, and hence they are generally used as adjuvants 75. Notable 
exceptions are the use of interferon (IFN)-α2b (Intron A), currently approved by the 
FDA for the therapy of hairy cell leukemia (HCL), AIDS-related Kaposi’s sarcoma, 
follicular lymphoma, multiple myeloma, melanoma and cervical intraepithelial 
neoplasms 76, and the use of IL-2 (Proleukin), which has, as single agent,  therapeutic 
activity in patients with metastatic renal cell carcinoma or malignant melanoma 77. 
 
- Immunomodulatory mAbs. This class of mAbs are able to interact with soluble or 
cellular components of the immune system, altering their functions 78. There are four 
general strategies: (1) the inhibition of immunosuppressive receptors expressed by 
activated T lymphocytes, such as cytotoxic T lymphocyte-associated protein 4 (CTLA4) 
79 and programmed cell death 1 (PD-1) 80; (2) the inhibition of the principal ligands of 
these receptors, such as the PD-1 ligand (PD-L1) 81; (3) the activation of co-stimolatory 
receptors expressed on the surface of immune effector cells, such as tumor necrosis 
factor receptor superfamily 82; (4) the neutralization of immunosuppressive factors 
released in the tumor microenvironment, such as transforming growth factor β1 
(TGFβ1) 83. The first of these approaches, commonly referred as “checkpoint blockade”, 
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has been shown to induce robust and durable responses in cohorts of patients with a 
variety of solid tumors 84. The anti-CTLA4 mAb Ipilimumab (Yervoy) was licensed by the 
FDA in 2011 for use against unresectable or metastatic melanoma 85, while the anti-PD-
1 mAb Pembrolizumab (Keytruda) was approved by FDA in 2014 for the treatment of 
advanced or unresectable melanoma patients who fail to respond to other therapies  
86. Preclinical data suggest that combining checkpoint blockers with co-stimulatory 
mAb has better antineoplastic effects 87. 
 
3.2 Passive immunotherapy 
- Tumor-targeting mAbs. This form of anticancer immunotherapy is the best 
characterized and perhaps the most widely employed in the clinic 88. There are at least 
five functionally distinct tumor-targeting mAbs variants: (1) naked mAbs that inhibit 
signaling pathways required for the survival or progression of neoplastic cells, but not 
of their non-malignant counterparts, such as the epidermal growth factor receptor 
(EGFR)-specific mAb Cetuximab, which is approved by the FDA for the treatment of 
head and neck cancer and colorectal carcinoma 89,90; (2) naked mAbs that activate 
potentially lethal receptors expressed only on the surface of malignant cells, such as 
Tigatuzumab (CS-1008), a specific mAb for a member of tumor necrosis factor receptor 
superfamily (TRAILR2) that is currently under clinical development 91; (3) immune 
conjugates, i.e. TAA-specific mAbs coupled to toxins or radionuclides, such as 
Gemtuzumab ozogamicine, an anti-CD33 calicheamicin conjugate currently approved 
for use in acute myeloid leukemia patients 92; (4) naked TAA-specific mAbs that 
opsonize cancer cells and hence activate  antibody-dependent cell-mediate cytotoxicity 
(ADCC) 93, antibody-dependent cellular phagocytosis 94, and complement-dependent 
cytotoxicity (CDC) 95, such as the CD20-specific mAb Rituximab, which is currently 
approved for the treatment of B-cell lymphomas, chronic lymphocytic leukemia and 
non-Hodgkin lymphoma 96,97; (5) and finally the so called “bispecific antibodies” formed 
by chimeric proteins consisting of two single-chain variable fragments from distinct 
mAbs, one targeting a TAA and one specific for a T cell surface antigen (for example 
Blinatumomab, a CD19- and CD3 bispecific antibody recently approved for the therapy 
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of Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia) 
98.  
The selection of tumor antigens suitable for antibody targeting and therapy, requires a 
comprehensive analysis of their expression on tumor and normal tissue, and their 
biologic role in tumor growth. If the mAb has to bind to cell surface receptors to 
activate or inhibit signaling, or to promote the ADCC or CDC, the antigen-mAb complex 
should not be rapidly internalized. Whether this is the case, the Fab and Fc regions 
have more chances to appropriately engage surface receptors, and immune effector 
cells and/or complement proteins, respectively. In contrast, the internalization is 
desirable for antibodies delivering toxins into cancer cell and for antibodies that 
downregulate cell surface receptors 99. 
 
- Adoptive cell therapy (ACT). Cancer immunotherapy using T cells represents a 
prominent form to treat malignant diseases and has multiple advantages compared to 
other immunotherapies: (1) T cell responses are specific and can distinguish cancerous 
from healthy tissue; (2) T cells responses are robust, they undergo up to 1,000-fold 
clonal expansion after the activation; (3) T cell response can traffic to the site of 
antigen expression, suggesting a mechanism for eradication of distant metastases; (4) T 
cell responses have memory, and thus maintain therapeutic effect for many years after 
initial treatment. ACT is conceptually distinct from dendritic cell-based approaches 
(which de facto constitute cellular vaccines without an intrinsic anticancer activity 100) 
and allogenic hematopoietic stem cell transplantation (which can be employed for the 
therapy of hematopoietic tumors 101) as it involves the isolation and expansion of 
autologous circulating or tumor-infiltrating lymphocytes from patient’s blood or tumor, 
their activation ex vivo against defined tumor antigens and their subsequent re-
administration to the lymphodepleted patients, most often in combination with 
immunostimolatory agents such as massive doses of IL-2 52. Rosemberg and colleagues 
demonstrated that the infusion of autologous ex vivo expanded tumor-infiltrating 
lymphocytes (TIL) can induce objective clinical responses in metastatic melanoma 102. 
While these results represented a stunning breakthrough in melanoma treatment, the 
protocol could not be applied to patients who lacked readily detectable T cell 
responses, or to cancers in which TIL culture remained a challenge. For example, both 
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breast and colon cancers have been found to contain TILs; however, their antigen 
specificities are still incompletely defines, and a significant proportion of those 
lymphocytes has suppressive rather than anti-tumor activity 103. Recently, sufficient 
TILs were isolated from cholangiocarcinoma patients to induce remission, but 
responses to epithelial cancers cells remained rare 104. Tumor-specific T cell clones can 
be generated from repeated antigen-specific stimulation of patient-derived or donor-
derived T cells in vitro 105. For example, a recent pilot study explored the use of 
allogenic CD8+ T cells with activity against WT1 in leukemia patients. Clones were 
generated by leukapheresis of HLA-matched donor cells and repeated stimulation with 
autologous peptide-pulsed dendritic cells over several months. Adoptively transferred 
lymphocytes remained long-term detectable in patient blood, and transient responses 
were observed in 2/11 of these high relapse-risk patients, with stable disease observed 
in 3 others 29. Similar approaches have been used in melanoma 106 and ovarian cancer 
107. Genetic engineering improved the therapeutic potential of ACT endowing 
peripheral blood lymphocytes (PBLs) with features such as a unique antigen specificity 
108, an increased proliferative potential and persistence in vivo 109, an elevated tumor-
infiltrating capacity 110, and higher cytotoxicity 111.    
The specificity of T cells can be altered prior to re-infusion by genetically modifying 
them to express a high-affinity TAA-specific T cell receptor (TCR) 112, or a chimeric 
antigen receptor (CAR), a transmembrane protein composed of the TAA-binding 
domain of an immunoglobulin linked to one or more immunostimolatory domains of T 
cell signaling molecules 113. Several clinical trials have already demonstrated the 
therapeutic potential of T cells expressing transgenic TCR or CAR, in particular for 
patients affected by hematological malignancies 114. In spite of promising preclinical 
findings, the adoptive transfer of purified natural killer cells to cancer patients has 
been associated with limited therapeutic activity 115,116. Conversely, a subset of natural 
killer T lymphocytes called “cytokine-induced killer (CIK) cells” was first discovered in 
the 1990s and can be generated from lymphocytes by the timed addition of IFN-γ, a 
mAb directed against CD3 (OKT3) and IL-2 in vitro 117. Compared to standard 
lymphokine-activated killer (LAK) cells, numerous studies have demonstrated that CIK 
cells possess enhanced cytotoxic anti-tumor activity against different tumor cells both 
in vitro and in vivo 118. Furthermore, our laboratory demonstrated for the first time that 
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CIK cells express CD16 in a donor-dependent manner, and that the concurrent 
administration of therapeutic mAbs leads to a significant improvement of their 
antitumor activity, triggering a potent ADCC activity 119. Collectively, although no ACT 
protocol is currently approved by the FDA, adoptive cell therapy represents a powerful 
approach to expand  the benefits of cancer immunotherapy to non-responsive patients 
and non-immunogenic tumors, which  represent the  majority of human cancers. 
 
4. DEPDC1 
In 2007, Kanehira et al. 120 identified and characterized a novel gene, DEPDC1 (DEP domain 
containing 1) significantly overexpressed in the great majority of bladder cancer cells, but  not 
expressed in normal human tissues, except the testis. The up-regulation of DEPDC1 was found in 
other several types of human cancers including multiple myeloma, breast cancer, hepatocellular 
carcinoma, lung adenocarcinoma and glioblastoma 121–125. Furthermore, a high expression of 
DEPDC1 is also associated with worse prognosis in patients with multiple myeloma and 
hepatocellular carcinoma 121,125. Recent studies demonstrated that DEPDC1 is  upregulated also in 
breast cancer brain metastasis compared with non-neoplastic tissues 126. Located in 1p31.2, 
DEPDC1 has two transcriptional variants, denoted as DEPDC1 isoform 1 (DEPDC1-V1: GeneBank 
Accession AB281187) and DEPDC1 isoform 2 (DEPDC1-V2: GeneBank Accession AB281274) 
consisting of 5318 and 4466 nucleotides that encode 811 and 527 amino-acid proteins (93.1 KDa 
and 61.5 KDa, respectively). The DEPDC1-V1 variant consists of 12 exons while DEPDC1-V2 isoform 
lacks exon 8 (852 nucleotides). Both variants contain a highly conserved DEP domain, and interact 
in the nucleus with the zing finger transcription factor ZNF224 120 (Figure 5).  
 
 
Figure 5. Genomic and protein structures of the two variants of DEPDC1 (DEPDC1-V1 and 
DEPDC1-V2). Gray boxes indicate coding regions, and white boxes indicate non-coding regions. 
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Black box indicates DEPDC1-V1-specific exon 8 (852 bp). The DEP domain is underlined (16-104 
amino acids). Image from Kanehira et al. Oncogene, 2007. 
 
Proteins containing the DEP (Dishevelled, EGL-10, Pleckstrin) domain have been reported to 
regulate a broad range of cellular functions including a large number of signaling proteins. The DEP 
domain is a module of approximately 90 amino acids first identified in Drosophila Melanogaster 
Dishevelled, known to be an adaptor in the Wnt signaling 127, in C. Elegans EGL-10, a negative 
regulator of G-protein coupled receptors signaling 128, and in mammalian Pleckstrin, which 
modulates signaling in platelets and neutrophils 129. Although DEPDC1 contains a highly conserved 
DEP domain, its biological functions and pathophysiologic roles in growth of human cancer cells 
are poorly known, with nowadays only few published reports showing its role in apoptosis and 
mitotic progression. In bladder cancer, DEPDC1 is associated in the nucleus with the 
transcriptional repressor ZNF224 to inhibit the transactivation of A20, which normally inhibits the 
phosphorylation of IκB-α (the inhibitor of NF-κB) and subsequently blocks its ubiquitination and 
proteasomal degradation 130. The suppression of A20 transcription results in NF-kB activation and 
translocation in the nucleus where it mediates the activation of anti-apoptotic pathways 131 
(Figure 6). 
 
 
 
Figure 6. Schematic presentation of the DEPDC1-ZNF224 complex signaling pathway for bladder 
cancer cells. Image from Harada et al. Cancer Res. 2010. 
 
In addition, studies using HeLa cells showed that DEPDC1 was highly expressed in the mitotic 
phase of the cell cycle, and that its knock down resulted in remarkable mitotic defects such as 
abnormal multiple nuclei and multipolar spindle structures accompanied by the up-regulation of 
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the A20 gene, as well as cycle-related genes 132. Recent studies have shown that DEPDC1 plays key 
roles in the regulation of MCL1, a member of anti-apoptotic BCL-2 family proteins 133, and seems 
to be a downstream molecule in the MELK-signaling pathway 134, which is reported to be 
upregulated in various types of human cancer and is known to be associated with cancer 
progression, maintenance of stemness and poor prognosis 135,136. In endometrial endometrioid 
carcinoma (EEC), a novel Protocadherin-DEPDC1-caspase signaling regulatory axis was suggested 
to contribute to EEC development and progression through the inhibition of apoptosis, which in 
turn leads to increase of tumor cells growth 133. Moreover, DEPDC1 itself has a significant function 
in cancer cells growth/survival, as its siRNA-mediated knock-down suppressed tumor cells growth 
and increase the number of apoptotic cells in bladder cancer and multiple myeloma 120,121. 
DEPDC1 knock down in myeloma cells also resulted in increased expression of mature plasma cell 
markers and therefore it could contribute to the plasmablast features of multiple myeloma cells 
found in some patients with adverse prognosis, blocking the differentiation of malignant plasma 
cells and promoting cell cycle 121. Collectively, these studies support the involvement of DEPDC1 in 
many aspects of cancer traits, such as cell proliferation, anti-apoptosis and cell invasion, 
suggesting that it may play key roles in tumorigenesis and might serve as novel target for the 
diagnosis and/or treatment of cancers. Besides, a DEPDC1-derived peptide vaccine restricted for 
the HLA-A*2402 molecule has been shown to effectively induce peptide-specific cytotoxic T 
lymphocytes in 66.7% (4/6) of advanced bladder cancer patients, leading to a stable disease and 
increase of overall survival without any adverse effect 137. Moreover, a phase I clinical trial of a 
five-peptide cancer vaccine (five HLA-A*2402-restricted TAA epitope peptides from KOC1, TTK, 
URLC10, DEPDC1 and MPHOSPH1) combined with chemotherapy in patients positive for HLA-
A*2402 with locally advanced, metastatic, and/or recurrent gastrointestinal, lung or cervical 
cancer is now ongoing. Preliminary results have shown that treatment was well tolerated without 
any therapy-associated adverse events above grade 3, and that TAA-specific T cell responses 
induced by vaccine were significantly associated with longer survival 138.       
 
5. Triple-negative breast cancer 
Triple-negative breast cancers (TNBCs) are characterized by the lack of estrogen receptor (ER), 
progesterone receptor (PR) and human epidermal growth factor receptor type 2 (HER2) 
expression 139. TNBC is an aggressive cancer that occur in approximately 15% of all patients with 
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breast cancer 140, with an higher incidence in young and African American women 141. Women with 
triple-negative breast cancer do not benefit from hormonal treatments or molecularly targeted 
therapies such as Tamoxifen or Trastuzumab, because they lack the appropriate targets for these 
drugs. Although sensitive to chemotherapy, early relapse is more likely in patients with TNBC than 
with other breast cancer subtypes 142, and visceral metastasis, including brain and lung metastasis, 
is commonly seen 143, all features that reflect the intrinsically adverse prognosis associated with 
the disease. 
 
6. Digital pathology and multispectral imaging 
Pathology has significantly changed over the last decades and, as a result of the technological 
developments in molecular pathology and genetics, aims to become quantitative and to provide 
more information about protein expression on a cellular level in tissue sections. The advent of 
digital imaging and computer analysis methods started a new era in pathology, beginning in 
research and moving slowly but steadily into clinical practice. Therapies like ipilimumab and 
nivolumab  have shown the potential for approaches that direct the patient’s own immune system 
against tumors 144. The complex repertoire of immune cells infiltrating many primary tumors are 
considered to be indicative of a spontaneous host immune response to tumor antigens 145; 
therefore, the idea that the T cell environment in primary tumors could have a prognostic value 
and might also be of predictive significance is now increasingly spreading. Studies performed in 
solid tumors have shown that infiltration of the tumor by T cells, especially CD3+ and CD8+ T cells, 
is associated with good prognosis 146,147,148. On the other hand, adverse effects of TILs are also 
documented, such as the presence of large numbers of regulatory T cells or myeloid-derived 
suppressor cells that clearly correlate with poor survival 149. However, further advances in the 
understanding of microenvironment role on tumor progression/regression will require a detailed 
characterization of the location and status of immune cells in the tumor landscape and their 
interaction with tumor cells. To address this issue, methods which provide phenotyping of 
immune and cancer cells combined with the cytoarchitectonics of the tumor become necessary. 
Until recently it was difficult, if not impossible, to phenotype immune cells in solid tumors while 
maintaining cellular spatial relationships and morphological context. Both flow cytometry and 
next-generation sequencing can phenotype cells, but only in disaggregated tissues, and standard 
pathological analyses can deliver morphology without being able to analyze complex phenotypes. 
23 
 
Standard immunohistochemistry methodologies can be used on tissue sections to visualize or 
quantify one marker at a time, but standard methods cannot capture the complex, multimarker 
phenotypes needed to analyze the subsets of immune cells that are important in cancer 
immunology 150. To address this issue, multispectral quantitative digital pathology imaging 
approach allows the visualization and quantification of biomarkers and protein expression in situ. 
This technique enables the development of multiplexed immune cell and protein expression 
profiling assays for cellular phenotyping in the tumor and tumor microenvironment of standard 
formalin-fixed paraffin-embedded (FFPE) tissue sections, maintaining the tissue architecture and 
the morphology 151. This provides spatial information that can lead to a better understanding of 
the distribution, the role, the types and the density of immune cells within primary tumors or 
metastasis. Vasaturo et al. 152 used the multispectral approach to quantify CD3+ T cells infiltration 
in primary tumors of metastasized patients using the ratio of intratumoral versus peritumoral T 
cell densities (I/P ratio). The authors showed that patients with longer survival had higher number 
of infiltrating T cells than patients with shorter survival, confirming that I/P ratio was the strongest 
predictor of survival in a multivariate analysis. Studies in breast cancer revealed that in patients 
not achieving a pathologic complete response after neoadjuvant chemotherapy, the density of 
both CD8+ and CD4+ infiltrates in the stroma were significantly greater than in the tumor. 
Conversely, for patients achieving a pathologic complete response, no significant difference in 
densities of stromal and intratumoral CD8+ or CD4+ was observed, suggesting that T cell infiltration 
from the stroma into the tumor is critical for successful neoadjuvant chemotherapy in breast 
cancer 153. With similar approaches, Oguejiofor at al. demonstrated that stromal infiltration of 
CD8+ T cells is associated with improved clinical outcome in HPV-positive oropharyngeal squamous 
carcinoma 154.  
 
6.1 Fluorescent multiplex immunohistochemistry with Tyramide Signal Amplification (TSA) 
Multispectral immunohistochemistry (mIHC) technique enables the simultaneous detection of 
up to six immunohistochemically labeled proteins, plus counterstain, onto single FFPE tissue 
sections, saving valuable tissues and enabling full contextual exploration of multiple cell types 
and functional states, and cell-to-cell interactions that are difficult or impossible to obtain 
with other methods 155. mIHC is based on detection via indirect immunofluorescence involving 
primary and secondary antibodies to facilitate signal amplification. In the protocol, an HRP-
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conjugated secondary antibody binds to an unconjugated primary antibody specific for the 
target/antigen of interest, and the detection is ultimately achieved with a fluorophore-
conjugated tyramide molecule that serves as the substrate for HRP. Activated tyramide forms 
covalent bonds with tyrosine residues on the protein of interest and is permanently deposited 
on the antigen site. This can markedly enhance the level of signal amplification, and the 
permanent nature of the tyramide-antigen binding allows for heat-mediated removal of 
primary/secondary antibody pairs, while preserving the antigen-associated fluorescence 
signal, making this process amenable to multiple rounds of staining in a sequential fashion 
(Figure 7). Importantly, one of the key advantages of this method is that multiple primary 
antibodies of the same species can be used without the concern for crosstalk. 
 
 
Figure 7. Basic principles of tyramide-based fluorescent mIHC. 
 
The mIHC workflow incorporates three essential elements: 
- Multiplex staining of FFPE tissue slides, even with multiple antibodies raised in the 
same species. The approach involves detection with TSA-reactive fluorophores that 
covalently label the epitope, followed by microwave treatment (MWT) for removal of 
primary and secondary antibodies, of any non-specific staining and reduction of tissue 
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auto-fluorescence. The TSA signal is largely unaffected by MWT and antibody removal. 
After MWT, another round of staining can be performed for additional target detection 
without risk of antibody cross-reactivity. 
- Multispectral imaging eliminates fluorophore crosstalk and interference from tissue 
auto-fluorescence, allowing precise measurement of each fluorescence signal within a 
tissue sample. A critical aspect of multispectral imaging and an essential component 
for obtaining quantitative results is the generation of correct spectral libraries for each 
fluorophore, including any background or intrinsic signal such as melanin or tissue 
autofluorescence, which means the correct separation of all the fluorescence signals 
within the sample. Once correct spectral signatures are present, the individual images 
corresponding to the intensity contributions of each fluorophore are extracted from 
the multispectral data set using linear unmixing 156. 
- Image analysis software that determines the intensity values per-cell and per-
subcellular compartment. This information is used in combination with user-trainable 
machine learning algorithms to phenotype cells, recognize morphologic regions of the 
tissue (e.g. tumor and stroma), and provide cell counts and densities within each 
region, together with the per-cell quantitation of many markers simultaneously. 
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AIM OF THE STUDY 
 
In recent years, the field of cancer immunotherapy has considerably expanded with the 
development of several new treatment options, including cancer vaccines, adoptive cell transfer, 
CAR T-cell therapy, immune checkpoint inhibitors and monoclonal antibodies 157. For the majority 
of patients, monotherapy may be relatively ineffective, and thus a combination of multiple 
therapeutic approaches may be required 158. Recent studies demonstrated that immune 
checkpoint inhibitors can generate and/or amplify an immune response against mutated antigens 
159,160. Accordingly, the combination therapy with immune checkpoint inhibitors and cancer 
vaccine or adoptive transfer of enriched populations of neoantigen-reactive T cells, may function 
synergistically to induce more effective antitumor immune responses 161. However, therapeutic 
developments targeting clonal neoantigens in order to design personalized immunotherapies to 
treat patients with advanced cancer are typically unwieldy, time-consuming and expensive 162. 
Thus, the identification of universal TSA shared by multiple patients and/or multiple tumors is of 
great importance to overcome the practical limitations of personalized cancer immunotherapy. 
Furthermore, the identification and selection of TSA playing a key role in tumor cell proliferation 
and survival are considered crucial to overcame the immune escape, as they downregulation or 
loss is expected to impair tumor progression 163. One promising universal TSA could be DEPDC1, as 
studies show its almost ubiquitous expression in cancer, and support its involvement in many 
aspects of cancer traits, such as cell proliferation, anti-apoptosis and cell invasion, suggesting that 
it may play key roles in the tumorigenesis process. 
In this study, we focused our attention on TNBC since no hormonal treatments or targeted 
therapies are currently available, as cancer cells lack the appropriate targets for these drugs 164. In 
this regard, the identification of new potential targets for immunological interventions could offer 
a therapeutic option and result in improved clinical outcomes for this aggressive and deadly form 
of breast cancer. 
Therefore, the aim of the PhD project was the identification of potential immunogenic DEPDC1-
derived epitopes presented in the context of the HLA-A*0201 allele, being this latter the most 
common MHC-class I subtype in Caucasian population 165, to be used for the development of new 
immunotherapeutic strategies for HLA-A*0201 patients with TNBC. However, in order to enhance 
the therapeutic potential of antigen-specific cytotoxic T lymphocytes directed against tumor cells, 
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a detailed understanding of the tumor microenvironment including the characterization of the 
immune cells phenotype and their local distribution and cell-to-cell interactions, becomes crucial. 
For this purpose, I spent three months in Paris in the laboratory of Prof. Jerome Galon, one of the 
pioneers of the digital pathology applied to cancer-immunology for patient stratification according 
to the immune status of tumor microenvironment. During this period, I gained confidence with 
novel multispectral immunohistochemistry (mIHC) technologies, which allow the visualization and 
quantification of different cell phenotypes simultaneously in the same FFPE tissue section, 
maintaining the tissue architecture and the morphology. Exploiting this expertise, we will be able 
to investigate the relationships established between adoptively transferred cytotoxic T 
lymphocytes and triple negative breast cancer cells, both in tumor-bearing mice and in humans.  
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MATERIALS AND METHODS 
 
1. cDNA microarrays analysis 
The Oncomine database, a repository for published cancer-profiling cDNA microarray data 166 
(http://www.oncomine.org), was explored for DEPDC1 mRNA expression in various human 
tumors, and in the corresponding non-neoplastic tissues. Statistical analysis of the differences in 
DEPDC1 expression was accomplished through the use of the ONCOMINE algorithms, which allow 
multiple comparisons among different studies 167,168. The fold change and gene rank were defined 
as “all”, whereas the data type was restricted to mRNA. Only studies with results achieving a 
P<0.05 were considered.  
 
2. Western blot 
Total cell extracts from tumor cells were obtained with a buffer containing 50 mM Tris HCl pH 7.5, 
2 mM EDTA, 150 mM NaCl, 1% NP-40 and 1% protease inhibitor cocktail (Roche Biochemical 
Reagents). Protein concentration was determined by BCA Protein Assay Micro Kit (Serva 
Electrophoresis). Lysates were resolved by SDS-sample buffer 4% sodium dodecyl sulfate (SDS), 
200 mM Tris HCl pH 6.8, 3% β-Mercaptoethanol, 6% glycerol and 0.6% Bromophenol Blue, all from 
Sigma-Aldrich, boiled for 5 minutes before loading in NuPage Novex 4-12% Bis-Tris Midi Protein 
gels (Invitrogen), and then transferred to the nitrocellulose membrane (PerkinElmer). DEPDC1 
expression was assessed in non-neoplastic samples using a commercially available tissue 
microarray (ProSci) containing nine human normal tissues (bladder, breast, cervix, kidney, ovary, 
placenta, prostate, testis and uterus. Western blot analysis was performed according to standard 
procedures using a rabbit anti-DEPDC1 polyclonal antibody (1:500, Abcam) and HRP-conjugated 
goat anti-rabbit IgG (diluted 1:3000, Abcam) secondary antibody. The membrane was developed 
with ECL detection reagents (ThermoFisher Scientific) and visualized using chemiluminescence. 
Signal intensity was measured by a Bio-Rad XRS chemiluminescence detection system (Lyfe 
Science Group).  
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3. Cell lines 
The following cell lines were used in this study: the human triple negative breast cancer (TNBC) 
cell line MDA-MB-231 (HLA-A*0201+), and the related derivatives MDA-MB-231 shDEPDC1 and 
MDA-MB-231 shCTRL that are stably transduced with a short hairpin RNA (siRNA) for  DEPDC1 
silencing or a control siRNA, respectively; the human TNBC cell line MDA-MB-468; MCF-7, a human 
breast cancer cell line; the human bladder cancer cell line SW-780; U87MG, a human glioblastoma 
cell line; HeLa, a human cervix adenocarcinoma cell line; HCT-15, a human colorectal 
adenocarcinoma cell line; MKN-45, a human gastric cancer cell line; K562, a human chronic 
myelogenous leukemia cell line; HepG2, a human hepatocellular carcinoma cell line; A549, a 
human lung carcinoma cell line; A375, a human melanoma cell line; SKOV-3, a human ovarian 
carcinoma cell line; T3M4, a human pancreatic adenocarcinoma cell line; PC-3, a human prostate 
carcinoma cell line; the human embryonic kidney cell line 293 (HLA-A*0201-) and 293-A2 (stably 
expressing the HLA-A*0201 molecule upon transfection); the T2 cells (HLA-A*0201+), a TAP-
deficient human hybrid B/T lymphoblastic cell line; the mouse fibroblast cell line NIH 3T3 and NIH 
3T3-A2 (stably expressing HLA-A*0201 upon retroviral transduction, see below). Cells were 
maintained in DMEM (MDA-MB 231, MDA-MB-468, MCF-7, SW-780, U87MG, HeLa, HepG2, A549, 
A375, 293 and NIH 3T3) or RPMI 1640 (HCT-15, MKN-45, K562, SKOV-3, T3M4, PC3, T2) medium 
(EuroClone) supplemented with 10% Fetal Bovine Serum (FBS, Gibco), 2 mM L-Glutamine, 10 mM 
HEPES, 100 U/ml Penicillin and 100 U/ml Streptomycin (all from Lonza), at 37°C in a 5% CO2 
atmosphere. 
 
4. Peptide selection and synthesis 
Several 9-mer HLA-A*0201 binding motifs from DEPDC1 protein sequence were selected based on 
a integration of their score using the HLA peptide binding prediction algorithms available at BIMAS 
(http://www-bimas.cit.nih.gov/molbio/hla_bind/)169, NetMHC 
(http://www.cbs.dtu.dk/services/NetMHC/)170 and NetCTL 
(http://www.cbs.dtu.dk/services/NetCTL/)171 websites. A total of 10 HLA-A*0201-restricted 
peptides were chosen. The DEPDC1-derived HLA-A*2402-restricted peptide EYYELFVNI served as  
negative control in the T2 stabilization assays. All peptides were synthesized by CRIBI (Padova, 
Italy) with a purity of 98% verified by mass spectrometry analysis. The peptide SLYNTVATL (HIV-1 
p17 Gag, aa 77-85; named Gag-1777-85) was used as negative control in functional assays, as it was 
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previously described as an optimal HLA-A2-restricted CTL epitope 172–174. The HLA-A2-restricted 
peptide ELAGIGILTV (Melan-A/MART-1 analogue, aa 26-35*A27L; named Melan-A26-35*A27L) was 
used for the generation of Melan-A-specific T cells for in vivo experiments 175. 
 
5. T2 stabilization assay 
Binding and stabilization of HLA-A*0201 molecule by DEPDC1-derived peptides was evaluated 
using T2 cells 176. T2 cells were stripped in 0.131 M citric acid, 0.066 M Na2HPO4 (pH 3.3) for 45 
sec, washed and resuspended in serum-free culture media. A total of 2x105 cells were incubated 
with 3 μg/ml β2-microglobulin (Sigma-Aldrich) and 100 μg/ml peptide in a final volume of 500 μl 
for 4 hours at 37°C. Cells were then washed and stained with the FITC-conjugated HLA-A*0201 
monoclonal antibody BB7.2 (Biolegend) before cytometry evaluation (FACSCalibur, BD 
Biosciences). Stabilization was calculated by dividing the Mean Fluorescence Intensity (MFI) of 
peptide-pulsed T2 cells with the MFI of T2 cells loaded with a negative control peptide (EYYELFVNI) 
with no predicted binding affinity to HLA-A*0201 177. 
 
6. Generation of peptide-specific T cells from healthy donors 
CD8+ T cells and monocyte-derived dendritic cells (DCs) were obtained from peripheral blood of 
HLA-A*0201 positive healthy donors. Peripheral blood mononuclear cells (PBMCs) were isolated 
by Ficoll-Plaque PLUS (GE Healthcare) density gradient centrifugation, and then separated by 
adherence to plastic culture flasks (Falcon) for 1.5 hours at 37°C in 5% CO2 to enrich the monocyte 
fraction. Non-adherent cells were collected and purified for CD8+ T cells using MACS CD8 
microbeads (Miltenyi Biotec) according to manufacturer’s instructions. Isolated CD8+ T cells were 
cryopreserved until further use. The adherent fraction was differentiated into mature dendritic 
cells by culture in RPMI 1640 supplemented with 8% Human AB serum (HS; Aurogene), 2 mM L-
Glutamine, 10 mM HEPES, 100 U/ml Penicillin, 100 U/ml Streptomycin and 50 μM 2β-
mercaptoethanol for 7 days with the addition of 1000 U/ml granulocyte-macrophage colony-
stimulating factor (GM-GSF) and 500 U/ml IL-4 (PeproTech). After 5 days, 1 μg/ml of LPS was 
added, and the DC’s mature phenotype at day 7 was confirmed by flow cytometry analysis of the 
expression of CD14 (clone TUK4; Miltenyi), CD83 (clone HB15; Miltenyi), CD86 (clone FM95; 
Miltenyi), CD80 (clone L307.4; BD Biosciences), CCR7 (clone G043H7; BioLegend), HLA-ABC (clone 
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W6/32; BioLegend) and HLA-DR (clone L243; BioLegend) markers. Mature DCs were pulsed with 20 
μg/ml of synthesized peptides in presence of 3 μg/ml β2-microglobulin (Sigma) in RPMI 1640 
medium supplemented with 3% HS at 37°C for 4 hours. These peptide-pulsed DCs were then 
irradiated (55 Gy) and mixed at 1:10 ratio with autologous CD8+ T cells on 24 well plates (Falcon)  
in a final volume of 2 ml of complete medium supplemented with 8% HS, 10 ng/ml IL-7 
(PeproTech) and 20 U/ml rhIL-2 (Proleukine, Novartis). After 2 days, half of medium was replaced 
with fresh medium supplemented with 100 U/ml IL-2. On days 7, 14 and 21, T cells were 
restimulated with the autologous peptide-pulsed DCs as described above (Figure 8). 
 
 
Figure 8. Ex vivo protocol for the generation of peptide-specific T cells from healthy donors 
peripheral blood. 
 
7. Generation of EBV-transformed B cell lines (LCL) 
For LCL generation, 10x106 fresh PBMC from HLA-A*0201 healthy donors were infected with 
supernatant from the B95-8 EBV producer cell line (ATCC), as previously reported 178. The day 
after, 0.7 μg/ml Cyclosporin A (Sigma-Aldrich) was added and cells were plated at 1x105 cells per 
well in flat-bottomed 96-well plates containing RPMI 1640 medium (EuroClone) supplemented 
with 10% Fetal Bovine Serum (FBS, Gibco), 2 mM L-Glutamine, 10 mM HEPES, 100 U/ml Penicillin 
and 100 U/ml Streptomycin (all from Lonza). 
 
8. Intracellular cytokine staining for interferon-γ (IFN-γ) detection 
IFN-γ production by DC/peptide-stimulated T cell cultures was measured by intracellular cytokine 
staining after blocking the cellular secretion using BD Cytofix/Cyotperm kit, according to the 
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manufacturer’s instructions. HLA-A*0201 positive LCL or tumor target cell lines were used as 
stimulators. LCL cells were pulsed overnight with each peptide (10 μg/ml), washed and incubated 
at 1:1 ratio with peptide-specific CTLs stimulated 3 times with autologous peptide-pulsed DCs. The 
Gag-1777-85 peptide served as negative control, while phorbol 12-myristate 13-acetate (PMA; 40 
ng/ml)/ionomycin (4 μg/ml) (Sigma Aldrich) as positive control. After 1 hour, cellular cytokine 
secretion was blocked by the addiction of GolgiStop (2 μM) and the incubation was allowed to 
continue for 5 hours at 37°C. Cells were then stained with APC-conjugated anti-CD8a antibody 
(clone RPA-T8; BioLegend), washed and fixed. After permeabilization, cells were stained with a PE-
conjugated anti-IFN-γ antibody (clone B27; BioLegend) for 30 minutes at 4°C, and flow cytometry 
analysis was performed (FACSCalibur, BD Biosciences).  
 
9. MHC-biomonomer and MHC-tetramer preparation 
The synthesis of MHC-peptide tetrameric complexes is based on the use of prokaryotic expression 
systems for MHC class I heavy chain and β2-microglobulin [JM109(DE3), Promega]. The MHC 
heavy chain (HLA-A*0201) was modified by substitution of the transmembrane and cytosolic 
domains with a signal sequence containing a biotinylation site for the enzyme BirA. The MHC 
heavy chain, β2m and epitope peptide (DEPDC1#5 or Melan-A26-35*A27L peptides) were subjected to 
a refolding in vitro in Tris-HCl pH 8, L-Arginin-HCl, NaEDTA, oxidized glutathione and reduced 
glutathione (Sigma-Aldrich). The complex was isolated through dialysis, concentrated and purified 
by HPLC to separate monomers from unconjugated components. Monomers were then 
enzymatically biotinylated by the enzyme BirA. The biomonomers obtained were purified and 
subsequently quantified with a spectrophotometer. The tetramers were finally assembled with 
phycoerythrin (PE)-conjugated extravidin (Sigma-Aldrich) to be detect by flow cytometry. The 
MHC-tetramers obtained were stored at 4°C. The efficiency of tetramerization and hence the 
correct volume of extravidin-PE to add was verified by ELISA. Briefly, 96-well plates (Maxisorb, 
NUNC) were coated overnight at room temperature (RT) with rabbit anti-human β2 microglobulin 
antibody (1:5000 in PBS 1X; Genetex), which recognizes β2 microglobulin of free biomonomers. 
The coating was then removed and the assay buffer (AB: PBS 1X, 2% BSA, pH 7.4) was added for 1 
hour at RT to saturate the aspecific sites. After three washes with wash buffer (WB: Tris HCl 50 
mM, 0.2% Tween 20, pH 7.4), serial dilutions starting from 1 µg/ml of tetramers or the 
corresponding biomonomers were added for 1 hour at RT. The biomonomer solutions were used 
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as positive controls. The plates were then washed three times with WB and Poly-Horseradish 
Peroxidase-Streptavidin antibody (1:15000 in AB; Endogen) was added for 1 hour at RT. After 
three washes with WB, OPD solution (o-Phenylenediamine dihydrochloride, Sigma-Aldrich) was 
added for 3 minutes for the detection of peroxidase activity. The reaction was finally stopped with 
HCl 3N and the absorbance was read at 490 nm in the ELISA plate reader (Victor X4 Multilabel 
Plate Reader; PerkinElmer). 
 
10. Peptide-specific T cell characterization  
T cells generated in vitro were characterized using the following fluorochrome-conjugated 
monoclonal antibodies: APC-conjugated CD3 (clone UCHT1), CD28 (clone CD28.2) and CD8 (clone 
RPA-T8; all Biolegend); FITC-conjugated CD16 (clone 3G8; Biolegend) and CCR7 (clone G043H7; 
Biolegend) and CD11a (clone HI111 RUO; BD Biosciences); PerCP-Cy5.5-conjugated CD56 (clone 
B159; BD Biosciences) and CD45RA (clone HI100; Biolegend); BV421-conjugated CD8 (clone RPA-
T8; BD Biosciences); APC-H7-conjugated CD4 (clone RPA-T4; BD Biosciences); PE-conjugated CD4 
(clone RPA-T4), CD44 (clone BJ18), CD62L (clone DREG-56) and CD83 (clone HB15e; all Biolegend). 
For the tetramer staining, CTLs were incubated with the PE-conjugated HLA-A*0201-DEPDC1#5 or 
PE-conjugated HLA-A*0201-Melan-A26-35*A27L tetramer. Samples were analysed by LSRII flow 
cytometer (BD Biosciences) and evaluated with FlowJo software (TreeStar Inc.).  
 
11. Transduction of NIH 3T3 with pBABE_puro_HLA-A*0201 retroviral vector 
The pBABE_puro retroviral construct containing the human HLA-A*0201 sequence (kindly 
provided by Prof. Dolcetti, Aviano, Italy) was packaged using the second-generation retrovirus 
producers cell line Phoenix (ATCC). Packaging cells were transfected at approximately 70% of 
confluence with 20 μg retroviral plasmid DNA using the calcium phosphate technique. After 48 
hours, the virus-containing medium was collected, filtered through a 0.45 μm filter and added to 
NIH 3T3 cells in presence of 8 μg/ml polybrene (Sigma-Aldrich) for 16 hours at 37°C. Fresh medium 
was then added and the cells were incubated for a further 24 hours in virus-free media prior to 
trypsinization and plating in media supplemented with 1.5 μg/ml Puromycin (Sigma-Aldrich) to 
select the cells expressing the HLA-A*0201 molecule. NIH 3T3 cells positive for HLA-A*0201 
expression were then analyzed by flow cytometry. 
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12. 51Cr-release assay 
DEPDC1#5 peptide-specific CTL cytotoxic activity was assessed using a 6 hours 51Cr-release assay. 
Briefly, a total of 1x106 target cells were labelled with 100 μCi of Na251CrO4 for 1 hour at 37°C and 
washed twice with culture medium. Depending on the experiment, target cells were incubated 
with 10 μM of DEPDC1-derived or Gag-1777-85 peptides for 40 minutes at 37°C and then washed 
twice. For blocking experiments, target cells were incubated for 30 min on ice with 10 μg/ml anti-
MHC-class I blocking antibody (W6/32 clone; Biolegend) or the relative isotype control (mouse 
IgG2a, κ isotype ctrl; Biolegend). Target and effector cells were then plated in a 96-well U-bottom 
plate at the indicated E/T ratio in a total volume of 200 μl. After a 6 hours incubation at 37°C, 30 µl 
supernatant was transferred on a scintillation plate (Perkin Elmer), and measured using a Top 
Count gamma counter (PerkinElmer). The percentage of lysis was calculated as follows: % Specific 
Lysis = (experimental release – spontaneous release) / (maximal release – spontaneous release) x 
100. Spontaneous and maximal releases were obtained by incubating target cells in medium alone 
or in RPMI 2% SDS, respectively. Alternatively, cytotoxicity was also expressed as lytic units 30 
(LU30), where 1 LU30 was defined as the number of effector cells capable of killing 30% of target 
cells 179. In this case, results were expressed in number of LU30 per 106 responder cells.  
 
13. Outgrowth assays 
Target MDA-MB-231 or NIH 3T3 cells were serially double diluted into replicate flat-bottom 96-
wells plate starting from 3000 cells/well, and T cells were added where indicated at 3000 
cells/well. Plates were incubated at 37°C in 5% CO2 with weekly refeeding, and target cells 
outgrowth was scored after 4 weeks. 
 
14. In vivo experiments of adoptive immunotherapy  
On day 0, 6-8 week-old female NOD/SCID common γ chain knockout (NSG, Charles River) mice 
were anesthetized (1-3% isoflurane, Merial Italia), and injected into the mammary fat pad with 
1x106 MDA-MB-231 cells transduced with a lentiviral vector coding for the Firefly Luciferase 
reporter gene 180. At day 3, mice were injected intra-tumorally with 10x106 DEPDC1-specific CTLs 
stimulated 3 times with autologous peptide-pulsed DCs, or with Melan-A-specific CTLs in the 
control group. A group of mice received only PBS 1X as negative controls. The same treatment was 
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repeated for 2 additional times at three-four day intervals. Tumor growth was monitored over 
time by bioluminescence analysis. In particular, anesthetized animals were given the substrate D-
Luciferin (PerkinElmer, MA, USA) by intraperitoneal injection at 150 mg/Kg in PBS (Sigma). The 
light emitted from the bioluminescent tumors or metastasis was detected using a cooled charge-
coupled device camera mounted on a light-tight specimen box (IVIS Lumina II Imaging System; 
Perkin-Elmer). Imaging times ranged from 15 s to 8 min. Regions of interest from displayed images 
were identified around the tumor sites or lymph node metastasis region, and were quantified as 
total photon counts or photon/s using Living Image® software (Perkin-Elmer). In lymph node 
metastasis detection, the lower portion of each animal was shielded before reimaging in order to 
minimize the bioluminescence from primary tumor, thus allowing the signals from metastatic 
regions to be observed in vivo.  
 
15. Statistical analysis 
Results were analyzed for statistical significance by using paired or unpaired Student t test and 
ANOVA, as appropriate (**** = P< 0.0001; *** = P< 0.001; ** = P< 0.01; * = P< 0.05). Histograms 
represent mean values ± standard deviation (SD). In scatter-plot graphs, symbols indicate different 
samples or assays, and horizontal bars represent means ± SD. Statistical analysis was performed 
using Sigmaplot and GraphPad Prism 4.0 softwares.  
 
16. Study approval 
Anonymized human buffy coats were obtained from the Blood Bank of Padova Hospital, and 
donors provided their written informed consents to participate in this study. Procedures involving 
animals and their care were in conformity with institutional guidelines that comply with national 
and international laws and policies (D.L. 26/2014 and subsequent implementing circulars), and 
the experimental protocol (Authorization n. 1143/2015-PR) was approved by the Italian Ministry 
of Health. 
 
17. 7-colors fluorescence multiplex immunohistochemistry  
Four μm-thick colorectal cancer (CRC) tissue sections on slides were heated in a dry oven at 56 °C 
for at least two hours, to allow drainage of melting paraffin. After three washes of 5 minutes each 
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in clearene (Leica Biosystems) to complete the removal of paraffin, the slides were hydrated 
through an ethanol gradient and finally washed with distilled water. The tissues were fixed to the 
slides, with a 20 minutes wash in 10% neutral buffered formalin (10% formalin, 4 g/L NaH2PO4, 6.5 
g/L Na2HPO4, pH7) and then rinsed with antigen retrieval pH6 (PerkinElmer) or pH9 (DAKO) 
solutions depending on the antigen to be detected. The antigen retrieval was brought at its boiling 
point using the microwave at 100% power and then left for other additional 15 minutes at 20% 
power. The microwave treatment served to quench endogenous peroxidase activity, for antigen 
retrieval and to remove antibodies after a target has been detected. After the slides were cooled 
at RT, they were incubated with Protein Block Serum Free (DAKO) for 10 minutes at RT and then 
washed with TBS 1X 0.04% Tween20 (TBST buffer). The tissue sections were completely covered 
with the primary antibody and incubated according to the manufacturer’s instructions regarding 
concentration, incubation time and temperature requirements. After 3 washes with TBST buffer, 
slides were incubated with anti-mouse or anti-rabbit HRP-conjugated secondary antibodies 
(DAKO) for 10 minutes at RT, and then washed 3 times with TBST buffer. The excess of wash buffer 
was drained off and Opal Fluorophores (PerkinElmer) were pipetted onto the slides and incubated 
at RT for 10 minutes. After 3 washes, the slides were placed in antigen retrieval buffer and the 
microwave treatment was repeated to strip the primary/secondary-HRP complexes to allow the 
next antigen staining. To detect other targets, the protocol was restarted from the blocking step. 
When all targets had been detected, DAPI Working Solution (PerkinElmer) was added for 5 
minutes at RT and the coverslips were put on the slides with mounting media. The visualization of 
7-colors Opal slides was performed using Mantra Quantitative Pathology Imaging System 
(PerkinElmer) and the analysis was carried out with inForm™ Tissue Finder™ image analysis 
software (PerkinElmer).     
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RESULTS 
 
1. DEPDC1 is widely expressed in tumors but not in normal tissues 
Using Oncomine database and gene data analysis tools, different public available microarray 
studies on cancer were checked to evaluate DEPDC1 gene expression 166,168. The analysis 
concerned the assessment of DEPDC1 mRNA expression levels for each of the studies considered. 
Fourteen independent data sets referring to different tumor histotypes showed a significant 
upregulation of DEPDC1 mRNA levels in primary cancers, as compared to normal counterpart 
tissues (P = 2.15E-7), (Figure 9 A) 181–193. Consistent with these findings, DEPDC1 protein was found 
to be expressed in a large set of different human tumor cell lines, such as breast, bladder, brain, 
cervix, colon, stomach, leukemia, liver, lung and melanoma cell lines (Figure 9 B), thus supporting 
the concept that DEPDC1 can be regarded as a potential “universal” tumor-associated antigen, 
whose expression is strictly linked to the neoplastic status. Conversely, DEPDC1 was not found to 
be expressed in a set of normal different human tissues (bladder, breast, cervix, kidney, ovary, 
placenta, prostate, and uterus; Figure 9 B), consistently with data reported by Kanehira et al 120. 
We failed, however, to visualize DEPDC1 protein in testis, while the specific mRNA had been 
previously detected by Northern blot, albeit at low levels, in the same normal tissue 120, likely due 
to the lower sensitivity of western blot.   
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Figure 9. DEPDC1 is upregulated in different human cancers. (A) DEPDC1 mRNA expression in 
normal (white) and tumor tissues (grey) as reported from microarray studies in the Oncomine 
database. Breast: (t-test= 10.953; P-value= 1.181E-14) 181; bladder (t-test= 6.217; P-value= 8.82E-9) 
182; brain (t-test= 9.929; P-value= 7.56E-12) 183; cervix (t-test= 7.688; P-value= 9.13E-9; 1) 184; colon 
(t-test= 3.978; P-value= 9.98E-5) 185; esophagus (t-test= 10.994; P-value= 8.17E-19) 186; stomach (t-
test= 7.378; P-value= 4.54E-10) 187; nasopharynx (t-test= 5.832; P-value= 1.71E-6) 188; leukemia (t-
test= 4.400; P-value= 8.57E-4) 189; liver (t-test= 6.180; P-value= 2.18E-7) 190; lung (t-test= 16.310; P-
value= 7.19E-18; 65 lung) 191; skin (t-test= 5.874; P-value= 3.54E-5) 192; Ovary (t-test= 14.643; P-
value= 2.12E-7) (TCGA Ovarian, No Associated Paper, 2013); Pancreas (t-test= 4.794; P-value= 
8.57E-6) 193. Numbers above each box plot refer to the number of samples reported. (B) 
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Endogenous expression of DEPDC1 protein in several human tumor cell lines (upper panels) and in 
different human normal tissues (lower panels), as assessed by western blot. MDA-MB-
231shDEPDC1 refers to cells with DEPDC1 silenced by shRNA, used as negative control. 
 
 
Moreover, DEPDC1 expression turned out to be associated with pathologic and prognostic 
parameters independent of the tumor type. Indeed, advanced stage (Table 1) and high grade 
tumors (Table 2) overexpress DEPDC1 mRNA as compared to early stage or low grade tumors, 
respectively.  
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Table 1. Upregulation of DEPDC1 mRNA levels in advanced stage cancers  
Tumor type 
Parameters for comparison 
(samples number) 
P-value 
Oncomine 
dataset 
Ref 
Lobular breast carcinoma N0 (7) vs N1 (12) 3.05E-4 
Lu, 
Breast 
194 
Ductal breast carcinoma M0 (176) vs M1+ (5) 0.009 
Bittner, 
Breast 
 
Large Cell Lung Carcinoma Stage I (11) vs Stage II (5) 0.018 
Hou, 
Lung 
195 
Lung Adenocarcinoma Stage I (168) vs Stage II (58) 5.17E-5 
Okayama, 
Lung 
123 
Oral Cavity Squamous Cell 
Carcinoma 
Stage III (3) vs Stage IV (7) 0.031 
Rickman, 
Head-Neck 
196 
Ductal Breast Carcinoma 
Stage I (24) vs Stage II (110) vs 
Stage III (42) vs Stage IV (5) 
0.006 
Bittner, 
Breast 
 
Anaplastic Medulloblastoma M0 (10) vs M1+ (7) 0.010 
Robinson, 
Brain 
197 
Cervical Squamous Cell 
Carcinoma 
Stage I (4) vs Stage II (11) vs 
Stage III (10) 
0.045 
Scotto, 
Cervix 2 
198 
Papillary Renal Cell Carcinoma 
Stage I (17) vs Stage III (8) vs 
Stage IV (7) 
4.57E-5 
Yang, 
Renal 
199 
Hepatocellular Carcinoma 
Stage I (106) vs Stage II (93) vs 
Stage III (39) 
0.023 
Jia, 
Liver 
200 
Borderline Ovarian Serous 
Tumor, Micropapillary Variant 
Stage I (6) vs Stage III (4) 0.078 
Anglesio, 
Ovarian 
201 
Pancreatic Ductal 
Adenocarcinoma 
Stage 0 (3)  vs Stage I (3) vs 
Stage IV (16) 
0.010 
Ishikawa, 
Pancreas 
202 
Endometrial Endometrioid 
Adenocarcinoma 
Stage I (30)  vs Stage II (5) vs 
Stage III (5) 
0.006 
TCGA, 
Uterus 
203 
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Table 2. Upregulation of DEPDC1 mRNA levels in high grade cancers 
Tumor type 
Parameters for comparison 
(samples number) 
P-value 
Oncomine 
dataset 
Ref 
Peritoneal serous 
adenocarcinoma 
Grade 2 (8) vs Grade 3 (14) 0.006 
Tothill, 
Ovarian 
204 
Invasive breast carcinoma Grade 2 (15) vs Grade 3 (16) 2.93E-6 
Stickeler, 
Breast 
205 
Invasive Ductal Breast 
Carcinoma 
Grade 1 (89) vs Grade 2 
(576) vs Grade 3 (857) 
1.49E-59 
 
Curtis, 
Breast 
206 
Bladder Urothelial Carcinoma 
Grade 1 (25)  vs Grade 2 
(37) vs Grade 3 (11) 
9.43E-11 
Lindgren, 
Bladder 
207 
Storiform-pleomorphic 
malignant fibrous histiocytoma 
FNCLCC Grade 2 (16) vs 
FNCLCC Grade 3 (54) 
1.24E-5 
Gibault, 
Sarcoma 
208 
Lung Adenocarcinoma Grade 2 (18) vs Grade 3 (14) 0.004 
Ding, 
Lung 
209 
Oligodendroglioma Grade 2 (38) vs Grade 3 (12) 4.29E-4 
Sun, 
Brain 
210 
Astrocytoma Grade 3 (24) vs Grade 4 (76) 4.07E-6 
Phillips, 
Brain 
211 
Infiltrating Bladder Urothelial 
Carcinoma 
Grade 3 (9) vs Grade 4 (3) 0.003 
Dyrskjot, 
Bladder 3 
212 
Meningioma 
Grade 1 (43) vs Grade 2 (19)  
vs Grade 3 (6) 
8.39E-6 
Lee, 
Brain 2 
213 
Gastric Cancer 
Grade 1 (13) vs Grade 2 (18)  
vs Grade 3 (25) 
0.035 
Takeno, 
Gastric 
214 
Papillary Renal Cell Carcinoma 
Grade 2 (22) vs Grade 3 (8)  
vs Grade 4 (3) 
3.30E-6 
Yang, 
Renal 
199 
Hepatocellular Carcinoma 
Grade 1 (12) vs Grade 2 (9)  
vs Grade 3 (12) 
1.76E-6 
Wurmbach, 
Liver 
190 
Ovarian Serous 
Adenocarcinoma 
Grade 1 (3) vs Grade 2 (55)  
vs Grade 3 (94) 
8.76E-5 
Tothill, 
Ovarian 
204 
Pancreatic Ductal 
Adenocarcinoma Epithelia 
Grade 1 (4)  vs Grade 2 (12)  
vs Grade 3 (11) 
0.007 
Collisson, 
Pancreas 
215 
Endometrial Endometrioid 
Adenocarcinoma 
Grade 1 (25) vs Grade 2 (67)  
vs Grade 3 (25) 
8.56E-5 
Bittner, 
Endometrium 
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Additionally, higher DEPDC1 mRNA levels are detected in primary tumor tissues from patients with 
metastatic events than in patients with no recurrence, and are related to a worst overall survival 
(Table 3).  
 
Table 3. Upregulation of DEPDC1 mRNA levels in patients with the worst outcome  
Tumor type 
Parameters for comparison  
(samples number) 
P-value 
Oncomine 
dataset 
Ref 
Invasive breast carcinoma 
No metastatic event at 1 year 
(191) vs metastatic event at 1 
year (6) 
0.004 
Schmidt, 
Breast 
216 
Activated B-cell-like diffuse 
large B-cell lymphoma 
No recurrence at 3 years (3) vs 
recurrence at 3 years (8) 
0.021 
Shaknovich, 
Lymphoma 
217 
Lung Adenocarcinoma 
No Recurrence at 3 Years (26) 
vs Recurrence at 3 Years (30) 
2.32E-4 
Lee, 
Lung 
218 
Lung Adenocarcinoma 
Alive at 1 Year (34) vs  
Dead at 1 Year (4) 
0.006 
Kuner, 
Lung 
219 
Clear Cell Renal Cell 
Carcinoma 
Alive at 5 Years (34) vs  
Dead at 5 Years (76) 
0.001 
Zhao, 
Renal 
220 
Diffuse Gastric 
Adenocarcinoma 
No Recurrence at 5 Years (6) vs 
Recurrence at 5 Years (12) 
0.002 
Forster, 
Gastric 
221 
Multiple Myeloma 
Alive at 1 Year (293) vs  
Dead at 1 Year (33) 
3.70E-6 
Zhan, 
Myeloma 2 
222 
Anaplastic 
Oligodendroglioma 
Alive at 1 Year (7) vs  
Dead at 1 Year (3)   
0.018 
Freije, 
Brain 
223 
Astrocytoma 
Alive at 5 Years (13) vs  
Dead at 5 Years (58)   
2.34E-4 
Phillips, 
Brain 
224 
 
 
Noteworthy, 13 independent datasets of human triple negative breast cancers (TNBC) show an 
overexpression of DEPDC1 compared to other breast cancer histotypes (Table 4).  
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Table 4. Upregulation of DEPDC1 mRNA levels in Triple Negative Breast Cancers  
Tumor type 
Parameters for comparison 
(samples number) 
P-value 
Oncomine 
dataset 
Ref 
Ductal Breast 
Carcinoma 
ERBB2/ER/PR Negative (18) vs  
Other Biomarker Status (19) 
4.97E-5 
Richardson, 
Breast 2 
181 
Invasive Ductal 
Breast Carcinoma 
ERBB2/ER/PR Negative (46) vs  
Other Biomarker Status (250) 
1.77E-16 
TCGA, 
Breast 
 
Invasive Breast 
Carcinoma 
ERBB2/ER/PR Negative (8) vs  
Other Biomarker Status (24) 
1.04E-4 
Stickeler, 
Breast 
205 
Ductal Breast 
Carcinoma 
ERBB2/ER/PR Negative (39) vs  
Other Biomarker Status (129) 
8.04E-9 
Bittner, 
Breast 
 
Invasive Ductal 
Breast Carcinoma 
ERBB2/ER/PR Negative (211) vs 
Other Biomarker Status (1,340) 
1.83E-43 
Curtis, 
Breast 
206 
Invasive Ductal 
Breast Carcinoma 
ERBB2/ER/PR Negative (57) vs  
Other Biomarker Status (106) 
2.09E-5 
Tabchy, 
Breast 
225 
Ductal Breast 
Carcinoma 
ERBB2/ER/PR Negative (80) vs  
Other Biomarker Status (32) 
1.31E-6 
Bonnefoi, 
Breast 
226 
Invasive Breast 
Carcinoma 
ERBB2/ER/PR Negative (178) vs 
Other Biomarker Status (320) 
4.45E-15 
Hatzis, 
Breast 
227 
Invasive Ductal 
Breast Carcinoma 
ERBB2/ER/PR Negative (73) vs  
Other Biomarker Status (495) 
7.17E-7 
TCGA, 
Breast 2 
 
Invasive Ductal 
Breast Carcinoma 
ERBB2/ER/PR Negative (5) vs  
Other Biomarker Status (29) 
0.005 
Zhao, 
Breast 
228 
Breast Carcinoma 
ERBB2/ER/PR Negative (19) vs  
Other Biomarker Status (87) 
7.86E-4 
Chin, 
Breast 
229 
Breast Carcinoma 
ERBB2/ER/PR Negative (32) vs  
Other Biomarker Status (295) 
2.36E-5 
Kao, 
Breast 
230 
Breast Cancer Cell 
Line 
ERBB2/ER/PR Negative (21) vs  
Other Biomarker Status (25) 
2.35E-4 
Neve, 
Cell Line 
231 
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2. In silico prediction of HLA-A*0201-restricted DEPDC1-derived peptides and assessment of 
their MHC stabilizing properties 
DEPDC1 amino acid (aa) sequence was analyzed for potential HLA-A*0201-restricted peptides 
using three epitope prediction algorithms available online, namely BIMAS, NetMHC and NetCTL. 
Different 9-aa peptides were classified according to their predicted ability to stabilize the MHC 
allele. The 10 peptides with the highest prediction score were chosen and synthesized for the 
subsequent studies (Table 5). Next, to evaluate their ability to stabilize the HLA-A*0201 allele, the 
DEPDC1-derived peptides were incubated with the antigen-processing deficient T2 cells. The HLA-
A*0201 expression levels were measured and compared to those induced by incubation of T2 cells 
with an irrelevant peptide (Table 5 and Figure 10). DEPDC1-derived peptides induced different 
levels of HLA-A*0201 stabilization, being DEPDC1#1 and DEPDC1#5 peptides those with the 
highest ability to stabilize the MHC molecule. 
 
Table 5. Candidate peptides derived from DEPDC1 sequence, their predicted binding affinities to 
HLA-A*0201 and stabilization ratios 
 
Peptide 
Start 
position 
Peptide 
sequence 
BIMAS 
score 
NetMHC 
Affinity 
(nm) 
NetCTL 
score 
Stabilization 
ratio on T2 
cells 
DEPDC1#1 673 FLMDHHQEI 728.022 6.05 1.4641 3.7 
DEPDC1#2 580 SMLTGTQSL 57.085 20.15 1.2956 2.6 
DEPDC1#3 588 LLQPHLERV 133.255 47.31 1.2127 2.5 
DEPDC1#4 574 SLLPASSML 79.041 37.72 1.1822 2.5 
DEPDC1#5 282 FLDLPEPLL 39.307 21.60 1.1503 2.9 
DEPDC1#6 289 LLTFEYYEL 54.474 41.23 1.1172 2.3 
DEPDC1#7 524 YINTPVAEI 15.177 165.46 1.0234 2.0 
DEPDC1#8 786 ALFGDKPTI 38.601 83.19 1.0145 1.3 
DEPDC1#9 618 LLMRMISRM 71.872 58.86 1.0108 2.1 
DEPDC1#10 562 RLCKSTIEL 21.362 127.36 0.9906 1.2 
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Figure 10. Comparison of the ability of different DEPDC1-derived peptides to stabilize the HLA-
A*0201 allele on the surface of T2 cells. Flow cytometry analysis reports the expression of HLA-
A*0201 on T2 cells (black line and related Mean Fluorescence Intensity, MFI) induced by the 
selected DEPDC1-derived peptides. An HLA-A*24-restricted DEPDC1-derived peptide was used as 
negative control (filled grey; MFI = 7.71).  
 
3. Generation of DEPDC1-derived peptide-specific T cell cultures 
Lymphocytes and monocytes were obtained from PBMCs of healthy donors. Monocytes were 
induced to differentiate into mature DCs to act as antigen-presenting cells for T cell stimulation. By 
flow cytometry, we first confirmed the DC maturation by the expression of CD83 and the absence 
of CD14 expressing cells; the increase expression levels of the co-stimulatory molecules CD80 (also 
known as B7.1) and CD86 (also known as B7.2), both upregulated during the DC activation and 
fundamental for the interaction with naïve T cells and, finally, the  expression levels of MHC-class I 
(HLA-ABC) and class II (HLA-DR) molecules and the chemokine receptor CCR7 (Figure 11).  
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Figure 11. Phenotypic characterization of monocytes-derived mature DC. Mean fluorescence 
intensity (MFI) of mature dendritic cells markers generated from human monocytes cultured in 
presence of GM-CSF, IL-4 and LPS (black line) and the isotype control (filled grey) assessed by flow 
cytometry analysis.  
 
The lymphocytes were immunomagnetically enriched for CD8+ T cells (80 ± 1.5% of total 
lymphocytes), being the remaining contaminant CD4+ T cell subset only fractional (7.6 ± 5.9%; 
Figure 12). To induce the expansion of antigen-reactive T cell populations, CD8+ T cells were 
stimulated weekly with the autologous DCs pulsed with the DEPDC1-derived peptides.  
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Figure 12. Assessment of immunomagnetic enrichment of CD8+ T cell populations. 
Representative flow cytometry analysis of lymphocytes isolated from PBMC of healthy donors 
before and after the enrichment with MACS CD8 microbeads, as described in Materials and 
Methods. Within each gate, the percentage of cells is reported. 
 
4. DEPDC1#5 peptide induces IFN-γ production in peptide-stimulated T cell cultures 
To evaluate which DEPDC1-derived peptide was able to induce a CTL functional response, at the 
third round of stimulation, T cell cultures were screened for IFN-γ production in response to HLA-
A*0201-positive lymphoblastoid cell line (LCL) cells pre-loaded with the different DEPDC1-derived 
peptides. The most responsive CD8+ population was observed after stimulation with DEPDC1#5 
peptide. LCL cells loaded with an irrelevant peptide (HLA-A*0201-restricted Gag-1777-85, 
SLYNTVATL) or left unpulsed did not induce IFN-γ production (Figure 13 A-B).  
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Figure 13. Identification of DEPDC1-derived immunogenic epitopes. (A) IFN-γ production from 
CD8+ T cells stimulated for 3 times with autologous DCs pulsed with each DEPDC1-derived peptide 
was measured in response to unpulsed or pulsed LCL cells, by cytokine intracellular staining. LCL 
cells loaded with Gag-1777-85 peptide served as a negative control. Data are presented as the 
percentage of CD8+ T cells positive for IFN-γ staining [** = P< 0.01; not statistically significant (p > 
0.05) if not indicated]. (B) Flow cytometry dot plots of intracellular IFN-γ detection in a DEPDC1#5 
peptide-derived T cell culture upon challenge with LCL cells pulsed with either DEPDC1#5 or Gag-
1777-85 peptide, or unpulsed. Within each gate, the percentage of IFN-γ producing CD8+ T cells is 
reported. The panel shows one representative experiment out of 6 performed.        
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5. Phenotypical characterization of DEPDC1#5-stimulated T cell populations 
The results from the intracellular staining for IFN-γ detection lead us to focus on and further 
characterize DEPDC1#5 peptide-restimulated T cell cultures. Figure 14A displays the flow 
cytometry gating strategy for phenotypical characterization of the cell cultures. In particular, after 
three stimulation rounds the bulk population was essentially composed of CD8+ T cells (79.4 ± 
1.5%; n = 24 donors), but a small fraction of CD4+ T cells was still present in the cultures (7.5 ± 
5.9%; n = 24 donors; Figure 14 B). Because of the different contribution of memory subsets in 
mediating antitumor immune responses 232, the differentiation state of T cells was investigated 
through the combined analysis of the chemokine receptor CCR7 and the CD45RA isoform, to 
distinguish CCR7+CD45RA+ naïve, CCR7+CD45- central memory (CM), CCR7-CD45RA- effector 
memory (EM) and CCR7-CD45RA+ terminally differentiated (Temra) cells 233. The majority of CD8+ 
lymphocytes after 3 weeks of cultures had an effector memory phenotype (78.48 ± 7%; n = 11 
donors; Figure 14 C), mainly with the lack of expression of both the lymphoid-homing marker 
CD62L and the co-stimulatory molecule CD28 (58.8 ± 17% CD62L-CD28- among CCR7-CD45RA- CD8+ 
T cells; n = 11 donors; Figure 14 D). A small group of CCR7-CD45RA- CD8+ T cells were CD62L-CD28+ 
(20.0 ± 16% CD62L-CD28+ among CCR7-CD45RA- CD8+ T cells; n = 11 donors) or CD62L+CD28+ (11.1 
± 8% CD62L+CD28+ among CCR7-CD45RA- CD8+ T cells; n = 11 donors; Figure 14 D), indicating 
subsets of “transitional” memory T cells, more differentiated than CM T cells but not as fully 
differentiated as EM T cells in terms of phenotype 234. NK cells (CD3-CD16+CD56+) and NKT cells 
(CD3+CD16+CD56+) were essentially undetectable in the cultures (data not shown).  
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Figure 14. Characterization of DEPDC1#5 peptide-specific T cell cultures. (A) Flow cytometry 
gating strategy for T cell subsets analysis. Numbers refer to percentage of positive cells. (B) Flow 
cytometry analysis of T cells subsets in cell cultures after 3 stimulations with autologous DCs 
pulsed with DEPDC1#5 peptide. The mean percentage and standard deviation are shown (n = 24 
healthy donors). (C) Percentages of CD8+ T cells within subsets defined by the expression of 
CD45RA and CCR7 differentiation markers CD45RA+CCR7+ naïve, CD45RA-CCR7+ central memory 
(CM), CD45RA-CCR7- effector memory (EM) and CD45RA+CCR7- terminally differentiated effector 
memory (Temra) cells]. The mean percentage and standard deviation are shown (n = 11 healthy 
donors). (D) Percentages of CCR7-CD45RA- effector memory CD8+ T cells within subsets defined by 
the expression of CD62L and CD28 markers The mean percentage and standard deviation are 
shown (n = 11 healthy donors). 
 
To evaluate the presence of antigen-specific T cells in culture, we took advantage of the tetramer 
technology in use in our laboratory. HLA-A*0201/DEPDC1#5-specific biomonomers were purified 
by HPLC to separate the fraction from unconjugated MHC heavy chains, β2-microglobulins and 
epitope peptides (Figure 15 A), and subsequently biotinylated. The biotinylated monomers 
obtained were then purified by HPLC (Figure 15 B) and the tetramers were obtained by the 
addition of Extravidin-PE. Finally, the efficiency of tetramerization was assessed by ELISA. As 
shown in Figure 15C, free biomonomers were undetectable in tetramer preparation, indicating 
that the tetramerization process was carried out with optimal efficiency. DEPDC1#5 peptide-
specific CD8+ T cells were then quantified by tetramer staining throughout the culture period. The 
amount of CD8+ T cells expressing a DEPDC1#5/HLA-A*0201-specific TCR reached a peak (1 ± 0.5%) 
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after three in vitro stimulations, and then slightly declined after the fourth stimulation (Figure 15 
D-E).  
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Figure 15. Tetramer staining of DEPDC1#5-specific T cell cultures. (A) HPLC purification of HLA-
A*0201/DEPDC1#5 monomers from unconjugated components. Vertical bars refer to the 
monomer fractions collected. (B) HPLC purification of biotinylated HLA-A*0201/DEPDC1#5 
monomers from free biotin. Vertical bars refer to the biomonomer fractions collected. (C) 
Tetramerization efficiency of DEPDC1#5-specific tetramer, as assessed by ELISA. The absorbance at 
490 nm of different dilutions (starting from 1 μg/ml) of the tetramer preparation (open circles) 
and biomonomer (filled circles) were compared. (D) Tetramer staining of CD8+ T cells after 
sequential rounds of stimulation. The mean percentage ± SD of CD8+/tetramer+ lymphocytes in 
cultures is shown for each stimulation. (E) Representative tetramer staining of DEPDC1#5 peptide-
stimulated T cell culture at day 0 (left) and after 3 stimulations (right), out of the 8 experiments 
performed.  
 
6. DEPDC1#5 peptide-stimulated CTL are HLA-A*0201-restricted, strictly antigen-specific and 
recognize an endogenously processed epitope in tumor cells 
Antigen specificity of CTLs stimulated with DEPDC1#5 peptide was assessed against the MDA-MB-
231 TNBC cell line, which is HLA-A*0201-positive and endogenously express DEPDC1 (Figure 16 A). 
Upon challenge with these cells, a consistent fraction of DEPDC1#5 peptide-induced CTL was 
stimulated to produce IFN-γ; on the other hand, the percentage of cytokine-producing CD8+ CTLs 
sharply dropped in response to MDA-MB-231 cells either pretreated with the anti-MHC class I 
W6/32 blocking antibody, or silenced for DEPDC1 expression by a specific short hairpin RNA 
(shDEPDC1). A control scrambled siRNA (shCTRL) produced no relevant effects on recognition 
(Figure 16 B). Additionally, a very limited IFN-γ response was observed against the human 
embryonic kidney 293 cell line, which endogenously express DEPDC1 (Figure 16 A) but is devoid of 
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the HLA-A*0201 molecule. Conversely, their stable transfection with the HLA-A*0201 allele (Figure 
16 C) led to a prompt and sustained recognition of target cells, and increased the percentage of 
IFN-γ+ responding CD8+ T cells (Figure 16 B). 
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Figure 16. Specific functional response of DEPDC1#5 peptide-stimulated CTLs. (A) Western blot 
analysis of DEPDC1 protein expression in MDA-MB-231 and 293 cell lines. MDA-MB-231shDEPDC1 
are silenced for DEPDC1, while shCTRL refer to cells silenced with a scrambled control siRNA. (B) 
Intracellular IFN-γ staining of DEPDC1#5 peptide-specific CD8+ T cells stimulated for 3 times with 
autologous DEPDC1#5 peptide-pulsed DC. Data are presented as the mean percentage ± SD of 
CD8+ T cells positive for intracellular IFN-γ staining (* = P< 0.05; n = 3 healthy donors). (C) HLA-
A*0201 expression on transfected (dotted lines) and untransfected (dark lines) 293 and NIH 3T3 
cell lines. MDA-MB-231 were used as positive control. 
 
In support of these data, the cytotoxic activity of DEPDC1#5 peptide-stimulated CTLs was assessed 
in a classical 51Cr-release assay. CTLs exerted a high cytotoxic activity against MDA-MB-231 cell 
line; such lysis was significantly reduced by DEPDC1 silencing, while the shCTRL did not affect the 
cytotoxicity, thus confirming antigen specificity (Figure 17 A). 
To further demonstrate that the CTL activity was specific for the DEPDC1#5 peptide, MDA-MB-231 
cells were pulsed with DEPDC1#5 or Gag-1777-85 peptides, and tested for susceptibility to lysis. In 
this condition, exogenous peptides bind to HLA-A*0201 and replace the endogenously presented 
peptides. CTLs exhibited a significantly higher lytic activity against DEPDC1#5-pulsed MDA-MB-231 
cells as compared to the same cells pulsed with the irrelevant HLA-A*0201-restricted peptide 
(Figure 17 B). As a confirmation of the HLA-A*0201 restriction, the incubation of MDA-MB-231 
cells with the W6/32 blocking antibody led to a significant reduction of cytotoxicity, an effect that 
was not observed with the addition of an isotype control antibody (Figure 17 C). Furthermore, 
DEPDC1#5 peptide-stimulated CTLs were significantly more cytotoxic against HLA-A*0201 
transfected 293 cells, which acquire the ability to present DEPDC1-derived peptides in the context 
of the HLA-A*0201 molecule, compared to wild type 293 cells that lack the expression of this allele 
(Figure17 D).  
The critical aspects of peptide specificity and HLA recognition were further confirmed by assessing 
the lytic activity of DEPDC1#5 peptide-stimulated CTLs against the NIH 3T3 murine fibroblast cell 
line, which does not express endogenously both human DEPDC1 and HLA-A*0201. CTLs did not 
disclose any relevant activity against wild type NIH 3T3 cells, but cytotoxicity significantly 
increased when target cells were simultaneously transfected with HLA-A*0201 (Figure 16 C) and 
pulsed with DEPDC1#5 peptide; HLA-A*0201-transfected NIH 3T3 cells unloaded or pulsed with an 
irrelevant peptide were essentially not recognized (Figure 17 E). 
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The differences in cytotoxic activity among experimental and control samples can be further 
appreciated when data are expressed in terms of LU30 (Figure 17 F-G). 
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Figure 17. Functional characterization of DEPDC1#5 peptide-stimulated CTLs. (A-E) Lytic activity 
and specificity of DEPDC1#5 peptide-stimulated CTL. Cytotoxicity of CD8+ T cells stimulated for 3 
times with autologous DEPDC1#5 peptide-pulsed DC was analyzed by a 6-h chromium release 
assays against the reported targets. Results are expressed as percentage of specific lysis at 
different effector-to-target (E/T) ratio [* = P< 0.05; ** = P< 0.01; *** = P< 0.001; **** = P<0.0001; 
# = P< 0.05, as referred to NIH 3T3-A2 DEPDC1#5 vs. NIH 3T3-A2 Gag-1777-85; not statistically 
significant (P > 0.05) if not indicated]. (F-G) Cytotoxicity data of curves in A-E are expressed as LU30 
[* = P< 0.05; *** = P< 0.001; **** = P<0.0001; not statistically significant (P > 0.05) if not 
indicated].  
 
7. DEPDC1#5 peptide-stimulated CTL restrain tumor growth in vitro 
To investigate the ability to induce long-term effects in vitro, DEPDC1#5 peptide-stimulated CTLs 
were co-cultured with MDA-MB-231 or NIH 3T3 in an outgrowth assay. After 4 weeks, both MDA-
MB-231 and NIH 3T3 reached the full confluency in the absence of lymphocytes. Conversely, the 
addition of DEPDC1#5 peptide-stimulated CTLs completely inhibited the growth of MDA-MB-231 
cells (Figure 18), even at very low effector/target ratios. Control CTLs represented by T cells 
redirected to the prostate-specific membrane antigen (PSMA) by transduction with a PSMA-
specific chimeric antigen receptor (CAR) 235, were not able to repress MDA-MB-231 growth, and 
served as control for antigen specificity (Ctrl-CTL). No effects were observed on NIH 3T3 cell 
growth (Figure 18). 
 
 
60 
 
 
Figure 18. In vitro tumor growth restraining activity by DEPDC1#5 peptide-specific CTLs. The 
figure reports the inhibition of MDA-MB-231 outgrowth by DEPDC1#5 peptide-specific T cells. 
MDA-MB-231 cultured alone or in presence of non-specific CTL (Ctrl-CTL), and NIH 3T3 cells alone 
or co-cultured with DEPDC1#5 peptide-specific CTL were used as negative controls. Results are 
expressed as percentage of target cell growth inhibition, and the numbers above each bar refer to 
the target:CTL ratio (n = 3 healthy donors).  
 
8. Set up of DEPDC1-unrelated peptide-stimulated T cell cultures as proper controls for adoptive 
immunotherapy 
Before proceeding with experiments aimed at assessing the in vivo therapeutic efficacy of anti-
DEPDC1 T cells upon adoptive transfer, unrelated control effectors were generated. Thus, CTL 
populations directed against the HLA-A2-restricted Melan-A26-35*A27L peptide were obtained 
following the same protocol used to generate DEPDC1#5 peptide-stimulated CTL, and the amount 
of CD8+ T cells expressing a Melan-A26-35*A27L/HLA-A*0201-specific TCR was quantified using 
tetramer staining throughout the culture period (25.7 ± 19.44% at the third round of stimulation, n 
= 3 healthy donors; Figure 19 A-B). The cytotoxic activity of Melan-A26-35*A27L peptide-stimulated 
CTL was assessed in a classical 51Cr-release assay to confirm that they didn’t recognize MDA-MB-
231 cells alone or pre-loaded with the DEPDC1#5 peptide. Conversely, if breast cancer cells were 
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pulsed with the Melan-A26-35*A27L peptide, the cytotoxicity was significantly increased (Figure 19 C-
D). 
 
 
 
 
Figure 19. Characterization of Melan-A26-35*A27L-stimulated CTL populations. (A) Tetramer staining 
of CD8+ T cells in cultures undergoing sequential rounds of stimulation. The mean percentage ± SD 
of CD8+/tetramer+ lymphocytes in cultures is shown for each stimulation. (B) The panel shows the 
tetramer staining of a representative Melan-A26-35*A27L peptide-stimulated T cell culture at day 0 
(left) and after 3 stimulations (right), out of the 3 experiments performed. (C) Lytic activity of 
Melan-A26-35*A27L peptide-stimulated CTL analyzed by a 6-h chromium release assays against the 
reported targets. Results are expressed as percentage of specific lysis at different effector-to-
target (E/T) ratio [* = P< 0.05; ** = P< 0.01; *** = P< 0.001; not statistically significant (P > 0.05) if 
not indicated]. (D) Cytotoxic activity as in (C) was expressed in terms of LU30 [* = P< 0.05; not 
statistically significant (P > 0.05) if not indicated]. 
62 
 
 
9. Adoptively transferred DEPDC1#5 peptide-stimulated CTLs inhibit breast cancer growth and 
restrain metastasis process 
The in vivo therapeutic efficacy of DEPDC1#5 peptide-stimulated and control CTL was evaluated 
against MDA-MB-231 cells stably transduced with the firefly luciferase (luc) reporter gene, and 
injected into the mammary fat pad of NSG female mice. Three days after inoculation, the tumor 
was detected by BLI and a group of mice (n = 9) received intra-tumor injections of DEPDC1#5 
peptide-stimulated CTLs for a total of 3 doses, whereas another group (n = 8) received CTL cultures 
stimulated against the irrelevant Melan-A26-35*A27L peptide; the untreated mice (n = 18) were 
injected with PBS (Figure 20 A). While a progressive increase in tumor growth was observed in the 
two groups of control mice, DEPDC1#5 peptide-stimulated CTL treatment was able to delay the 
primary tumor growth (Figure 20 B).  
When MDA-MB-231 cells are injected orthotopically into mammary fat pad in NSG mice, 
metastases are frequently observed 3-4 weeks later in the axillary lymph nodes and lungs 236–238. In 
this regard, mice treated with CTLs showed a significant reduction in peripheral metastatic  
colonization as compared to untreated mice and to mice treated with Melan-A-specific CTLs, when 
examined at the same primary tumor size (Figure 20 C), thus clearly indicating that DEPDC1#5 
peptide-stimulated CTLs were also effective in inhibiting metastases. 
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Figure 20. Assessment of therapeutic efficacy in vivo of DEPDC1#5 peptide-specific CTL. (A) On 
day 0, NSG mice were injected into the mammary fat pad with 1x106 luc-transduced MDA-MB-231 
cells, and were treated  intra-tumorally at days 3, 6 and 10 with 1x107 DEPDC1#5 peptide-specific 
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CTLs (n = 9) or Melan-A peptide-specific CTL  (n = 8). The untreated group of mice received 3 
injections of PBS1X (n = 18). (B) Tumor growth was monitored by BLI measurement as photon flux. 
Left panels show the primary tumor BLI of 3 representative mice for each group after 29 days from 
tumor injection, while right panel reports tumor growth of all animals at different time points 
(mean of photons/second ± SD; *** =  P < 0.001; the ANOVA was used for statistical analysis). (C) 
Distant metastatic colonization was evaluated by BLI when a primary tumor size of about 700 mm3 
was reached in each group. The left panels show the BLI of distant metastases in 3 representative 
mice for each group, while right panel reports the photons/second detected in each individual 
mouse belonging to the different groups (* = P < 0.05; ** = P < 0.01). 
 
10. Multispectral imaging and optimization of 7-colors fluorescence multiplex 
immunohistochemistry with Opal staining 
During my three-months training in Paris at the Prof. Galon’s laboratory, I learned the 
fundamentals of multispectral imaging using the PerkinElmer’s Opal multiplex 
immunohistochemistry (mIHC) technique on colorectal cancer (CRC) and adenoma tissue sections, 
an expertise that will be instrumental for further studies in the context of the current TNBC 
project. The mIHC enables simultaneous detection of multiple proteins of interest of formalin-
fixed paraffin-embedded (FFPE) tissue sections. In my protocol, an HRP-conjugated secondary 
antibody binds to an unconjugated primary antibody specific for the target/antigen of interest, 
and the detection is ultimately achieved with a fluorophore-conjugated tyramide molecule, 
allowing for serial stripping of the primary/secondary antibody pairs, while preserving the antigen-
associated fluorescence signal. PerkinElmer’s Phenoptics workflow enables imaging and analysis of 
up to six immunofluorescence markers, plus counterstaining, within intact FFPE tissue sections, 
saving valuable tissues and enabling full contextual exploration of multiple cell types, functional 
states and cell-to-cell interactions that are difficult or impossible to obtain by other methods. 
There are a number of considerations that can impact the success of a fluorescent mIHC 
experiment and, in Prof. J. Galon’s laboratory, I learned how to successfully optimize 7-colors 
multiplex assays. In this regard, a critical aspect of multispectral imaging and an essential 
component to obtain quantitative results is the generation of correct spectral libraries for each 
fluorophore, including any background or tissue autofluorescence, that means the correct 
separation of all of the fluorescence signals within the sample. Therefore, the optimal 
concentration of primary antibodies of the multiplex panels, by performing titrations for each 
individual component, and the optimal antibody-fluorophore pairing, in order to achieve the best 
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possible signal intensity and signal to noise ratio for each target of the panels, have to be 
evaluated. The final aim is to obtain a complete spectral library, including all the fluorescence 
signals present in the multiplex panel, necessary for accurate unmixing of Opal fluorophores and 
analysis of multiplex slides (Figure 21).  
 
 
Figure 21. Spectral library from a mIHC assay. An example of a CRC tissue slide with single staining 
for CD4-Opal620 and the extraction of the corresponding spectrum. (A) Original color (RGB) 
image; (B) unmixed Opal620 image showing CD4 expression; (C) unmixed image without tissue 
autofluorescence obtained from an unstained tissue section; (D) extracted spectrum of Opal620; 
(E) complete extracted spectral library, which include Opal520, Opal690, Opal570, Opal620, 
Opal650, Opal540, DAPI and tissue autofluorescence spectra. 
 
Once built an optimized spectral library, including the complete spectral proprieties of each 
independent signal necessary for spectral unmixing, multiplex staining of CRC and adenoma tissue 
slides had to be set up. In this regard, it is critical to optimize the order in which the antibodies in a 
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multiplex panel are applied to the tissue section, to ensure that multiple rounds of heating do not 
compromise target-specific epitopes. Once found the optimal antibodies order, I analyzed the 
multiplex stained slides with the Mantra quantitative pathology workstation, which enables 
isolation of individual colors to allow independent, noninterfering and precise measurement of 
protein expression, while eliminating background (Figure 22). 
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Figure 22. Example of 7-colors multiplex staining of CRC tissue sample. (A) Original RGB image; 
(B) unmixed image stained with CD3 (red), CD8 (green), PD-1 (white), X marker (yellow), Y marker 
(pink), cytokeratin (cyan), nuclei (blue).  
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Another important advance afforded by the imaging software, is the ability to take fluorescent IHC 
images and create simulated brightfield images. Since all images retain multispectral information, 
elements of the spectra can be used to simulate various brightfield views, such as H&E, or 
hematoxylin with DAB chromogen (Figure 23). 
 
 
Figure 23. Simulated IHC images. (A) Unmixed mIHC examining the expression of CD3 (magenta), 
CD8 (red), PD-1 (white), X marker (green), cytokeratin (cyan) and nuclei (blue) in CRC tissue. (B) 
Subsequent simulated hematoxylin and DAB staining indicating cytokeratin expression, (C) CD3 
expression, (D) CD8 expression and (E) PD-1 expression. 
 
Using the inForm™ Tissue Finder™ image analysis software, the image analysis starts with an 
automated tissue segmentation into regions of morphologically distinct architectures, such as 
tumor and stroma. Trainable pattern recognition makes this possible and avoids often 
prohibitively laborious manual identification of regions of interest (Figure 24 A). The training of 
morphologic software was done by drawing representative training regions on some images of the 
cohort, allowing the software to “learn” to recognize the morphologies of interest. The resulting 
image segmentation algorithm is then applied to each image. The next step is the identification 
and segmentation of individual cells, starting with nuclear and then membranous or cytoplasmic 
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segmentation. The expression of markers can be then read out on a per-cell and per-cell-
compartment basis (Figure 24 B). Once the parameters are known for each cell, further advanced 
machine learning approaches can then automatically “phenotype” cells into user-defined 
categories and, as Figure 24C shows, it is possible to visualize functional states, cell-to-cell 
interaction and the location of single cells within the tumor and in the stroma. Since the xy 
coordinates and the tissue context are preserved, a wide range of spatial and cellular interaction 
metrics can be explored: Figure 24D displays an example of a possible analysis that can be 
achieved with the exported data, allowing the quantification of different cell types in distinct 
morphological areas of the tumor microenvironment. 
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Figure 24. Image analysis of multiplex immunohistochemically stained sections. (A) Tissue 
segmentation. Tumor regions are shown in red, stroma in green, blood vessels in yellow and no 
tissue in blue. (B) Cell segmentation. Membranes are shown in red and nuclei in green. (C) 
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Phenotyping. CD3+/CD8- cells are shown in red, CD3+/CD8+ cells in green, CD3+/PD1+ cells in 
magenta, CD3+/CD8+/PD1+ cells in pink, CD3+/X+ cells in yellow, CD3+/CD8+/X+ cells in orange, CK+ 
cells in cyan and other cells in blue. (D) Example of a possible analysis resulted from exported 
data, in which specific cell types are quantified in different morphologically distinct regions of the 
tumor microenvironment. 
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DISCUSSION 
 
Generally, tumor-specific mutations represent ideal targets for cancer immunotherapy, since they 
are not present in healthy tissues and can potentially be recognized as neo-antigens by the T-cell 
repertoire. However, personalized vaccines against these specific mutated proteins are hampered 
by the fact that every patient’s tumor possesses a unique set of mutations, which must be first 
identified with enormous time-consuming and expensive molecular screenings. Therefore, the 
identification of tumor-specific antigens shared by multiple patients and by different types of 
cancers, is crucial to overcome these problems and to make immunotherapy universally 
applicable. The involvement of DEPDC1 in many aspects of cancer traits suggests its key role in 
tumor cell growth and survival 120,121, hence supporting a low possibility of antigen down-
regulation. Therefore, we investigated DEPDC1 gene expression among human cancer tissues 
using the Oncomine database, and found that it is overexpressed almost ubiquitously in human 
cancers as compared to the healthy counterpart tissues. This aspect, together with its involvement 
in the oncogenic process, strongly indicate that DEPDC1 can be regarded as a novel universal 
oncoantigen, potentially suitable for targeting many different tumors.  
Additionally, the pathologic and prognostic value of DEPDC1 up-regulation is consistently 
supported by its association with the most common clinic-pathological variables associated to 
cancer aggressiveness, such as the presence of regional nodal metastasis, invasion of distant 
organs and presence of poorly differentiated or undifferentiated abnormal-looking cells, and a 
significant correlation was demonstrated with both overall and disease-free survival. According to 
the predominant DEPDC1 overexpression in most aggressive tumors, its up-regulation was found 
to be particularly relevant in TNBCs, which are characterized by a poorer prognosis respect other 
forms of breast cancer, and associated with an increased risk of recurrence within 3 years from 
diagnosis and an increased 5-year mortality rate 140. In this regard, our study showed that a HLA-
A*0201-restricted DEPDC1-derived peptide could be exploited for immunotherapy against TNBCs, 
since nowadays no hormonal treatments or targeted therapies are available for such tumor as it 
lacks the appropriate targets for these drugs 164.  
We decided to focus on the HLA-A*0201 allele as it is the most common HLA class I subtype in the 
Caucasian population and the second most common in the Japanese population 165,239. Therefore, 
ten HLA-A*0201-restricted DEPDC1-derived peptides were identified by integrating the results of 
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three epitope prediction programs based on the prediction of peptide binding affinity to MHC, the 
probability of peptide proteasomal cleavage and the efficiency of peptide transport trough the 
endoplasmic reticulum. One of the peptides tested had the ability to induce a specific and relevant 
functional CTL response against target cells; indeed, DEPDC1#5-stimulated CTLs produced IFN-γ in 
presence of both target cells artificially loaded with the DEPDC1#5 peptide, and tumor cells 
endogenously expressing the DEPDC1 protein. Furthermore, despite the small percentage of 
tetramer-positive T cells, the DEPDC1#5-stimulated CTL populations exerted a relevant and 
specific cytotoxic activity against human triple negative breast cancer cells, indicating that TNBC 
cells naturally process the DEPDC1 antigen and present the epitope in association with the HLA-
A*0201 molecules, thus becoming susceptible to the CTL attack. These findings suggest that even 
a small fraction of antigen-specific T cells can exert a significant lytic function, likely due to the 
recycling potentialities of the effectors, ultimately leading to a marked enhancement of the overall 
activity of DEPDC1#5-specific lymphocytes. Nonetheless, the antigen specificity and HLA-restricted 
nature of the cytotoxicity were confirmed using target cells lacking the protein or the HLA-A*0201 
allele or both, which were not recognized by the CTL cultures.  
In an attempt to have access to a more representative and consistent effector population, we 
repeatedly tried to sort the DEPDC1#5 tetramer-positive subset from cultures; however, because 
of the lower sensitivity of the available instrument (MoFlo Astrios Cell Sorter, Beckman Coulter) as 
compared to the LSRII flow cytometry, we always failed in detecting and sorting any tetramer-
positive cell population. We also tried to isolate DEPDC1#5-specific T cell clones, but the number 
of T cells obtained was always largely insufficient to perform any additional experiment, in 
particular in vivo. The major problem for expansion was due to the limited availability of 
autologous dendritic cells required for T cell stimulation. Nonetheless, such material could be 
useful to isolate DEPDC1#5-specific TCRs for subsequent T cell engineering, even though the long 
steps of TCR gene cloning, expression in suitable viral vectors, transduction of activated T 
lymphocytes and assessment of their in vitro and in vivo functional activity were out of the scope 
of present work. 
Adoptive immunotherapy attempts to circumvent the insufficient T cell responsiveness to tumors 
by collecting the tumor infiltrating lymphocytes (TIL), providing them with the necessary 
stimulatory conditions for an optimal activation, and reinfusing into the patient. However, there is 
no certainty about the type of CD8+ T cells that would be the optimal for the treatment of cancer. 
Terminal effector T cells provide variable and often very short-lived protection against tumors in 
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both humans and mice 240,241. Therefore, the ex vivo enhanced survival and proliferative potential 
of memory T cells, as well as their ability to rapidly become reactivated upon secondary challenge, 
makes them a more promising choice for generating protective immunity against cancer. 
However, it remains uncertain whether their protective capacity can be attributed to one 
particular subset of memory T cells. Central memory T cells expand well in response to a 
secondary activation and survive for long periods, and hence they are likely to be good at 
protecting against large tumor burdens, metastasis and relapse 242. Conversely, effector memory T 
cells are able to exert immediate cytotoxic activity and should act rapidly to restrain the growth of 
existing tumors in isolated peripheral sites 243. After three in vitro stimulations with autologous 
peptide-pulsed DC, we obtained heterogeneous CD8+ T cell cultures, mainly composed by effector 
memory T cells, and in part by central memory and terminal effector T cells; it is not currently 
known whether just one or the other of the memory cell subsets is superior in providing 
protection against cancer, but a heterogeneous T cell population has the benefit to contribute the 
useful properties of both activated effector memory T cells that can immediately traffic to the 
tumor and destroy the cells, and central memory T cells that home to the lymph node where they 
can proliferate and be restimulated by incoming DC from the tumor site, leading to an expansion 
of the anti-tumor immune response.  
The functional response mediated by DEPDC1#5-stimulated CTL was not apparently a short-term 
effect, as completely inhibited in vitro breast cancer cell growth even at very low effector to target 
ratios. Moreover, in a TNBC mouse model DEPDC1-stimulated CTL delayed breast primary tumor 
growth and reduced peripheral colonization despite the apparently limited number of DEPDC1#5-
specific CD8+ T cells injected, thus demonstrating the effectiveness of the CTL therapy also in 
restraining of the metastasis process. Conversely, CTL populations directed against the well-known 
immunogenic Melan-A protein 175, which is not expressed in MDA-MB-231 cells 244, had no 
therapeutic effects despite the higher amount of Melan-A26-35*A27L specific CD8+ T cells infused, 
thus excluding a possible therapeutic effect of non-specific lymphocytes. 
In conclusion, we demonstrated that the HLA-A*0201-restricted DEPDC1#5 peptide is a putative 
tumor epitope that could be exploited in immunotherapy against different tumors overexpressing 
the DEPDC1 protein. Data from literature show that such results are per se sufficient to justify the 
transfer to the clinical setting and the starting of a vaccination clinical trial. With the specific 
regard to DEPDC1, Obara and colleagues 137 identified a HLA-A24-restricted epitope from DEPDC1 
through a genome-wide expression profile analysis of bladder cancer, and used it for vaccinating 
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patients. Notably, the overall preclinical assumptions were based on the in vitro establishment of 
four DEPDC1-specific CTL clones, which were simply tested for IFN- production and cytotoxicity 
against suitable targets. Thereafter, authors moved directly in vivo in bladder cancer patients, 
where they proved the immunogenicity of the peptide also following vaccination. Currently, we 
cannot advance a clinical trial with the identified DEPDC1#5 peptide, and therefore the only 
possibility we foresee to demonstrate its immunogenicity in vivo would be the identification of the 
potential mouse counterpart (if existing), and the carrying out of vaccination studies in mice. An 
alternative could be represented by immunization studies in HLA-A2-transgenic mice, but previous 
experiences in the lab with HHD mice (a transgenic strain carrying a hybrid Kb/HLA-A2 molecule) 
have been always quite unsuccessful. 
This is the main reason we decided to perform adoptive transfer experiments in vivo in tumor-
bearing mice, to provide insights about the potentiality of the identified antigenic epitope in 
eliciting a functional T cell population; indeed, since CTL proved to maintain a tumoricidal 
potential, this approach suggest that DEPDC1#5-expanded CTL cultures could be potentially 
suitable for ACT in TNBC patients and/or patients carrying DEPDC1-expressing tumors. A major 
problem for this approach, however, might be represented by the limited number of DEPDC1#5-
specific T cells obtained after the in vitro stimulations. Nonetheless, this might be due to the fact 
that our DEPDC1#5-specific CTL cultures were generated from healthy donor PBMC, in which 
DEPDC1-specific precursors were essentially undetectable at day 0. In this regard, it would be 
interesting to try to stimulate a potentially primed DEPDC1-specific T cell population derived from 
the peripheral blood or neoplasia of cancer patients with DEPDC1-positive tumors. This approach 
is currently ongoing in collaboration with colleagues at the National Cancer Institute in Aviano 
(CRO-IRCCS), and involves the stimulation of PMBC from TNBC patients, even though preliminary 
results are still elusive. Alternatively, a Rapid Expansion Protocol approach 245 could be tried, even 
though such technology is currently not set up in our laboratory.  
Moreover, as recent studies showed that therapy with immune-checkpoint inhibitors enhanced 
neoantigen-specific T cell reactivity, a possible shortcut to bypass the availability of limited 
amounts of expanded DEPDC1#5-specific CTL populations for adoptive transfer in patients, could 
rely on combination therapeutic approaches with immune-checkpoint inhibitors currently in 
clinical use, such as the monoclonal antibodies Ipilimumab (anti-CTLA-4), MDX-1106 (anti-PD-1) or 
BMS-936559 (anti-PD-ligand1 [PD-L1]) 246, capable of enhancing antigen-specific T cell reactivity 
and  inducing more effective antitumor immune responses.  
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As an alternative, cloning the TCR from DEPDC1#5-reactive T cells to be used for genetically 
engineering patient T cells could represent an option to generate large amounts of effectors, even 
though the requirement of specialized GMP facilities and the strong safety problems associated to 
the genetic manipulation of donor lymphocytes represent serious constrains for this approach. 
Nonetheless and taking together, the results of this study support the concept that DEPDC1 can be 
considered as a universal tumor antigen, and might represent a potential and safe target for 
treating many human tumor subtypes through immunotherapy, as its overexpression is confined 
only in tumor cells and not in normal tissues.  
As further advances in immunotherapy approaches require a detailed understanding of the tumor 
microenvironment, including the characterization of functional states of different immune cells, 
their spatial distribution and their interactions with tumor cells, we plan to employ an approach of 
multiplexing digital pathology to study the intimate relationships that adoptively transferred 
lymphocytes can establish with TNBC cells in tumor-bearing mice. Until recently, flow cytometry 
was the best methodology to obtain multicolor analysis required for the accurate characterization 
of the surface antigen profile of multiple cells simultaneously. However, flow cytometry can be 
less effective in the detection of extremely rare cell populations, and does not allow to assess the 
architectural relationships as the tissues must be disaggregated. To overcome this limitation, 
classical IHC can be used on FFPE tissue section, maintaining cellular spatial relationships. 
However, while chromogenic IHC is compatible with a limited number of antigen staining in the 
same slide, there are numerous benefits to adopt a multiplexing approach, which relies on 
tyramide-based fluorescent detection. Firstly, concurrent examination of 7 or more 
proteins/biomarkers, their spatial relationship and frequency of co-expression, all in the context of 
preserved tissue architecture, can offer insights into disease progression. Secondly, thanks to the 
covalent bond formation between multiple fluorophore-conjugated tyramide molecules and the 
tyrosine residues of the antigen of interest, the level of signal amplification is markedly enhanced, 
allowing the detection of extremely low expressed proteins. In addition, multiple primary 
antibodies of the same species can be used in a sequential fashion, simplifying the multiplex panel 
design. Notably, multiplex detection of 7 or more proteins relies on the unmixing of overlapping 
fluorophore emission spectra, which not only ensures that the signal from each protein of interest 
is differentiated from the rest, but also provides the ability to take into account and subtract the 
signal arising from tissue autofluorescence, enabling accurate fluorescence intensity quantitation 
in FFPE samples. Furthermore, the combination of multispectral imaging with software for 
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morphologic tissue area segmentation and cellular segmentation to perform quantitative per-cell 
and per-cell compartment intensity quantitation, provides researchers with phenotypic data about 
individual cells within particular morphologic regions of an image, rendering the cancer 
immunology knowledges more complete as compare to the multimarker information obtained 
with only the flow cytometry. Importantly, reliable image analysis can be controlled through 
standardization of the imaging protocols and fluorescent signal threshold imposition, as the same 
algorithm is used to analyze all the cohort slides. Finally, with mIHC and multispectral analysis 
integrated into the pathologists workflow, it is of great value collecting maximal information from 
a single tissue slide, as patient cancer tissue samples are rare. The benefits of this methodology, 
combined with the development of software for quantitation, are making fluorescent mIHC an 
increasingly powerful tool in the analysis and characterization of disease progression, enabling 
deeper insight into tissue and cellular processes, and ultimately supporting diagnostic potential in 
order to improve clinical care. The knowledge of this methodology, which provides phenotyping of 
immune and cancer cells combined with the cytoarchitectonics of the tumor, opens additional 
opportunities to further understand the tumor microenvironment dynamics and this will then be 
leveraged in analyses of multiple cancer types, both in human and in mouse. 
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ABBREVIATIONS 
 
TSA   tumor-specific antigens 
DEPDC1 DEP domain containing 1 
CTL  cytotoxic T lymphocytes 
TNBC  triple negative breast cancer 
NK cells natural killer cells 
IFN-γ  interferon-γ 
HLA  human leucocyte antigen 
TCR  T-cell receptor 
MHC  major histocompatibility complex 
TGF-β  transforming growth factor β 
MDSC  myeloid-derived suppressor cells 
Treg  regulatory T cells 
CTLA-4  cytotoxic T-lymphocyte antigen 4 
PD-1  programmed cell death protein 1 
TAA  tumor-associated antigen 
PSA  prostate specific antigen 
CEA  carcinoembryonic antigen 
WT1  Wilms tumor 1 
HPV  human papilloma virus 
IL  interleukin 
FDA  food and drug administration 
mAbs  monoclonal antibodies 
DC  dendritic cells 
APC  antigen-presenting cells 
GM-CSF granulocyte-macrophage colony-stimulating factor 
PD-L1   programmed cell death ligand 1 
EGFR  epidermal growth factor receptor 
ADCC  antibody-dependent cytotoxicity 
CDC  complement-dependent cytotoxicity 
ACT  adoptive cell therapy 
TIL  tumor-infiltrating lymphocytes 
CAR  chimeric-antigen receptor 
CIK  cytokine-induced killer cells 
LAK  lymphokine-activated killer cells 
EEC  endometrial endometrioid carcinoma 
ER  estrogen receptor 
PR  progesterone receptor 
HER2  human epidermal growth factor receptor type 2 
FFPE  formalin-fixed paraffin-embedded 
mIHC  multispectral immunohistochemistry 
HRP  horseradish peroxidase 
TSA  tyramide signal amplification 
MWT  microwave treatment 
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aa  amino acid 
PBMC  peripheral blood mononuclear cells 
LCL  lymphoblastoid cell line 
NSG  NOD/SCID gamma 
BLI  bioluminescence 
rhIL-2  recombinant human interleukin 2 
SD  standard deviation 
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